Trading Analysis Report: COHR¶

Generated: 2026-10-02 10:19:00

I. Analyst Team Reports¶

Market Analyst¶

Current Price: 319.19 (USD) Price As Of: 2026-10-01

COHR (Coherent Corp., NYQ) – Technical Report as of 2026-10-01¶

1. Summary¶

COHR closed at 319.19 on 2026-10-01, up from 287.81 the day before, a gain of about 10.9%. The bar opened at 290.00, ranged 286.42–323.23 and closed near its high. Volume was 11.39M shares, roughly double the 4–7M typical of recent September sessions.

The picture is mixed: - Higher timeframes are bullish. The weekly and monthly SuperTrend are both UP, and price sits above the 10 EMA, 50 SMA and 200 SMA. - The daily SuperTrend is still DOWN, with its stop at 332.01. - ADX is about 7, so there is no trend. The stock has been in a wide, volatile range, and today's move is a large breakout attempt inside that range, not yet a confirmed trend change.

2. Indicator selection¶

I chose a set that spans several categories and avoids redundancy: - Trend and regime: 10 EMA, 50 SMA, 200 SMA and the three-tier SuperTrend. - Trend strength: ADX. - Momentum: RSI and MACD. These come from the verified snapshot. - Volatility: Bollinger Bands and ATR, also from the snapshot. - Volume: OBV and MFI. - Exhaustion and stretch: TD-9 and Z-score.

3. Trend and moving averages¶

Indicator	Value	Price vs. level
10 EMA	298.12	Close is above it
50 SMA	296.55	Close is above it
200 SMA	288.23	Close is above it

Price is above all three averages. The 10 EMA is above the 50 SMA, which is above the 200 SMA, so the ordering is bullish.
The three averages sit within about 10 points of each other (288–298). That tight cluster fits the sideways, whipsawing action in the closes.
The closes show how choppy this has been:
2026-09-21: 321.52.
2026-09-24: 290.61.
2026-09-30: 287.81.
2026-10-01: 319.19.
The 200 SMA at 288.23 sits very close to the 2026-09-30 close of 287.81. That close was a hair below it, and price has since moved back above.

SuperTrend (14, 3x ATR): - Weekly (Tier 1): UP. The stop is 255.29, and the close is 25.03% above it. - Monthly (Tier 2): UP. The stop is 228.66, and the close is 39.59% above it. - Daily (Tier 3): DOWN. The stop is 332.01, and the close is 3.86% below it.

The higher tiers carry more weight, so the primary and regime trends are up. The daily stop at 332.01 is the line to watch. Today's high of 323.23 did not reach it. A daily close above 332.01 would flip the daily trend to UP and bring all three tiers into agreement.

4. Trend strength¶

ADX is 7.02 on 2026-10-01. It has stayed between about 5.9 and 11.5 throughout September, and its September peak was 11.54 on 09-03. That is far below the 20 threshold for a range-bound market and the 25 threshold for a tradable trend.

Trend-following signals such as MA crossovers and SuperTrend flips are unreliable in this regime.
This matches the whipsawing price, with sharp swings that have not extended into a trend.
I did not pull +DI or -DI, so I can't say which side currently has the edge.

5. Momentum¶

RSI is 56.55. This is neutral to mildly positive, with no overbought or oversold reading, so there is room to rise before 70.
MACD is 0.67, the signal line is -0.87, and the histogram is +1.54.
MACD is above its signal line with a positive histogram, so short-term momentum has turned up.
The MACD line is only just above zero. That means the 12/26 EMA spread is close to flat, which fits ADX at 7.
I did not pull the preceding days, so I can't confirm the exact day the cross happened.

6. Volatility¶

Band	Value
Upper	327.15
Middle (20 SMA)	294.59
Lower	262.03

The close of 319.19 is above the middle band and about 8 points below the upper band. It is not yet a band breakout.
The bands are about 65 points wide, roughly 22% of the middle band. That is wide, and it reflects how large the daily moves have been.
ATR is 21.37, about 6.7% of the close. Daily swings of this size are normal for COHR now, so stops sized inside one ATR (about 21 points) are likely to be hit by noise.
Today's range of 286.42–323.23 was about 36.8 points, well above ATR.

7. Volume flow¶

OBV is 303.6M, up from 291.9M on 09-28 and 292.2M on 09-30. It is still below the 312.3M reached on 09-21, when the close was 321.52. Today's volume has lifted OBV, but it has not yet confirmed a new high. The OBV line over the window is sideways to slightly higher, which matches the range-bound price.
MFI is 0.598 in this tool's output. The tool reports it on a 0–1 scale, not the conventional 0–100 scale, so this is about 60 on the usual scale. That is neutral and rising from 0.575 on 09-28. It was 0.31 on 09-01 and 0.70 on 09-21, so buying pressure has improved over the month without reaching overbought (above 0.8).
Today's roughly 11.4M volume on a close near the high is the strongest participation among the recent September sessions. Other sessions with 10M+ volume include 09-18 at 10.16M, a +7.2% day. The 11.4M on 10-01 is a point in favor of the breakout attempt.

8. Exhaustion and stretch¶

TD-9 (running counts): - Weekly: -3 (sell setup, 3 of 9). - Monthly: +3 (buy setup, 3 of 9). - Daily: -1 (sell setup, 1 of 9).

None of these is near a completed 9, so there is no exhaustion signal.

Z-score (20-period): - Weekly: -0.19, near the mean. - Monthly: +1.11. - Daily: +1.51.

The daily reading is elevated after today's jump but below the |2| stretch threshold. The weekly reading, which carries the most weight, is neutral. COHR is neither stretched nor oversold on the higher timeframes.

9. Price context from the data¶

Peak and trough:
Highest close in the pulled data: 426.89 on 2026-06-02.
Lowest close: 222.05 on 2026-07-29.
The current 319.19 sits roughly in the middle of that range.
Rebound:
Early August had a sharp rebound to 379.13 on 08-07.
That was followed by a slide to 264.41 on 09-03.
Closes then recovered into the 320s on 09-18 and 09-21.
September range: closes between 264.41 and 321.52. The range is wide, and price has repeatedly reversed inside it.

10. Levels, taken from tool output¶

Resistance: - 321.52 (2026-09-21 close). - 327.15 (upper Bollinger Band). - 332.01 (daily SuperTrend stop, a close above it flips the daily trend).

Support: - 298.12 (10 EMA). - 294.59 (Bollinger middle). - 296.55 (50 SMA). - 288.23 (200 SMA). - 287.81 (2026-09-30 close). - 262.03 (lower band). - 255.29 (weekly SuperTrend stop).

I have no tool evidence for historical bounces at these levels. They are reference points taken from the indicators and recent closes.

11. Scenarios¶

Bullish:
A daily close above 332.01 would flip the daily SuperTrend. It would also put price above the upper band and above the 09-21 close of 321.52.
It would be stronger if OBV makes a new high above 312.3M and ADX turns up from its lows.
The weekly and monthly trends are already UP.
Neutral:
Price stalls between about 294 and 327 as ADX stays under 20. Given September's pattern, this is the base case.
Bearish:
A close back below the 10 EMA, 50 SMA and Bollinger middle (about 294–298) would erase today's gain.
A close below the 200 SMA at 288.23 would put the 287.81 area in play again.
The weekly SuperTrend stop at 255.29 is the level that would challenge the higher-timeframe uptrend.

12. Caveats¶

A one-day jump of about 10.9% on roughly double normal volume can partly reverse. I had no news or fundamentals tool, so I can't say what drove it.
The system context lists today as 2026-10-02, but the analysis was run through the 2026-10-01 bar, which is the latest available.
The MFI tool output is on a 0–1 scale, unlike the 0–100 scale the indicator description uses. I read 0.598 as about 60 on the conventional scale.
The snapshot and the OHLCV pull agree on the 2026-10-01 close of 319.19.

13. Key points¶

Item	Reading	Takeaway
Close (2026-10-01)	319.19	Up about 10.9% from 287.81 on high volume (11.39M)
Day range	286.42–323.23	Closed near the high
Weekly SuperTrend	UP, stop 255.29 (+25.03%)	Primary trend up
Monthly SuperTrend	UP, stop 228.66 (+39.59%)	Regime up
Daily SuperTrend	DOWN, stop 332.01 (-3.86%)	Needs a close above 332.01 to flip
10 EMA / 50 SMA / 200 SMA	298.12 / 296.55 / 288.23	Price above all three, clustered
ADX	7.02	No trend, range regime
RSI	56.55	Neutral, room to run
MACD / signal / histogram	0.67 / -0.87 / +1.54	Momentum turning up
Bollinger (lower / mid / upper)	262.03 / 294.59 / 327.15	Price between mid and upper band
ATR	21.37 (about 6.7%)	High volatility, size stops accordingly
OBV	303.6M (09-21 peak 312.3M)	Improving, no new high yet
MFI	0.598 (about 60)	Neutral, rising
TD-9 (W / M / D)	-3 / +3 / -1	No exhaustion
Z-score (W / M / D)	-0.19 / +1.11 / +1.51	Not stretched
Resistance	321.52, 327.15, 332.01	Breakout zone
Support	298.12, 294.59, 288.23, 262.03, 255.29	Moving-average cluster, then lower band and weekly stop

Sentiment Analyst¶

Overall Sentiment: Mildly Bullish (Score: 6.0/10) Confidence: Low

Data limits (read first). Only one of three sources carries usable data. Yahoo Finance news was unavailable for 2026-09-24..2026-10-01 (a tool limitation on recent items, not an absence of COHR news). Reddit was skipped by configuration. StockTwits returned 17 messages, all dated 2026-10-01, so this is effectively a one-day snapshot rather than a full-week read. Confidence is low.

1. StockTwits (17 messages, all 2026-10-01). - Labeled sentiment: 3 Bullish (18%), 0 Bearish (0%), 14 unlabeled. With only 3 labeled posts, the 100/0 split among labeled messages is not statistically meaningful. - Bullish-tagged posts: @DignitaryFinancial ("I think that it breaks out here"); @DooScooby7 (Credo/DustPhotonics silicon photonics thesis, mentioning COHR only in a basket of tickers); @dukeofhb ("work it"). - Unlabeled posts lean positive in tone: @topstockalerts ("every consolidation seems to strengthen the case"), @dukeofhb ("how sweet it is. LFG"), and @Hello_AI (long positions up strongly since January, though doubting the news will "stay long"). - Cautionary or bearish-leaning content, all unlabeled: - @moostocks is exiting. The post cites operating cash flow of ~$80M, inventory up ~80% YoY to ~$2.6B, ~$3.2B of debt, heavy hyperscaler/AI exposure and a ~26x forward P/E. These figures come from the user and are not verified here. - @Sieppo sold 80% of the portfolio position at $319. The original target was the wedge ceiling near $330. They plan to wait for consolidation before re-entering. This is profit-taking, not a bearish call. - @cubie jokes that the sector needs funding from selling MU to keep rising. - @alienfromthefuture rotated profits into MNKD. - @MrMaglue's comment is ambiguous, but it hints at a sharp-move or fear dynamic.

2. News. Unavailable. I cannot confirm any institutional news flow from the tool output. The StockTwits posts reference these items secondhand, and none was verified: - A Citi report saying LITE and COHR could control ~80% of an optical-circuit-switching market that could reach ~$11B by 2030 (via @SkinnyDipping). - A Bernstein Outperform call on CLS, LITE, COHR and CIEN, with a COHR target of $350 (via @notreload_ai). - A Morgan Stanley note on possible FCC rules for optical transceivers (via @NeverFadeTheOracle).

3. Reddit. Skipped. There is no signal from r/wallstreetbets, r/stocks or r/investing.

Cross-source alignment/divergence. No cross-source comparison is possible. Within StockTwits, the tone is bullish and momentum-driven, while the one fundamental-based dissent (cash flow, inventory, leverage, valuation) and the profit-taking posts show some retail participants trimming near $319.

Dominant themes. - AI data-center optical buildout and the photonics sector rally (COHR trades alongside LITE, AAOI, CIEN, VIAV). - Analyst-driven catalysts (Citi, Bernstein), per secondhand citation. - Breakout and consolidation technical talk (a wedge ceiling near $330, a LITE breakout from a 5-month consolidation). - Sector rotation and funding, e.g. selling MU to buy photonics.

Catalysts. - Further analyst target raises, such as the $350 Bernstein target. - A sustained breakout above ~$330. - Continued AI capex momentum. - Optical circuit switching adoption.

Risks. - Valuation (~26x forward P/E per a user). - A working-capital and cash-flow squeeze (inventory build, weak operating cash flow). - Debt load. - Customer concentration in hyperscalers. - Possible FCC regulation of optical transceivers. - The sector-wide move looks crowded, and one-day sentiment can reverse. - Retail users take profits at round-number levels.

Summary table

Signal	Direction	Source	Evidence
Labeled retail sentiment	Bullish (tiny sample)	StockTwits	3 Bull / 0 Bear / 14 unlabeled of 17
Breakout/consolidation talk	Bullish	StockTwits	@DignitaryFinancial, @topstockalerts, @dukeofhb
Analyst catalysts (secondhand)	Bullish	StockTwits	Citi OCS 80% share claim; Bernstein Outperform, $350 target
Profit-taking	Cautious	StockTwits	@Sieppo sold 80% at $319; @alienfromthefuture rotated out
Fundamental concern	Bearish	StockTwits	@moostocks: OCF ~$80M, inventory ~$2.6B, debt ~$3.2B, ~26x fwd P/E
Regulatory risk	Cautious	StockTwits	Morgan Stanley / FCC optical transceiver rules (secondhand)
Institutional news	Unavailable	Yahoo Finance	Not served for the window
Reddit	Unavailable	Reddit	Skipped by config

Bottom line. The one-day retail read is mildly bullish, driven by sector momentum and analyst-call chatter. Evidence is thin and unverified, with visible profit-taking and one fundamentally grounded bearish post. Weigh this alongside fundamentals and technicals.

News Analyst¶

COHR (Coherent Corp.) news and macro report, week ending 2026-10-01¶

Summary¶

My tools returned very little usable data, so this report is thin. I have no COHR-specific news, no macro readings and no prediction-market odds for the week. Nothing below is fabricated, and I did not fill the gaps with guesses about prices, rates or company events.

What each tool returned¶

1. COHR company news: no data. - I tried two windows, 2026-09-24 to 2026-10-01 and 2026-09-01 to 2026-10-01. - Both returned: "Yahoo Finance news unavailable… it only serves recent items, so this is not an absence of news for COHR." - This is a tool limitation, so it says nothing about whether COHR had news. I can't report on earnings, guidance, analyst actions, AI/datacenter optical demand, or tariff and export-control developments for COHR.

2. Macro indicators from FRED: no data. - The fed funds rate, 10-year Treasury, CPI, unemployment, yield curve and VIX calls all failed with "FRED_API_KEY environment variable is not set." - I have no verified figures for policy rates, inflation, labor, curve shape or volatility.

3. Prediction markets: withheld. - The "Fed rate cut" and "recession 2026" queries were blocked for 2026-10-01. Polymarket serves only live odds, and serving them would leak post-date information into the analysis. - I have no market-implied probabilities.

4. Global news: returned, but little of it is relevant. The nine items from 2026-09-24 to 2026-10-01 were mostly small-cap mining and commodities press releases: - Silvercorp Metals, CUNICO Metals, Vizsla Copper, Finlay, Quartz Mountain and ACDC Metals (BLM drilling permits). - Greenland Mines reported critical-mineral additions, including gallium and vanadium, from its Skaergaard PGM program. This is the only item with a loose link to COHR. Gallium is a compound-semiconductor input, and Coherent works in compound semiconductors and photonics. The link is thematic only, since the item says nothing about COHR or supply. - Barchart published a September commodity winners-and-losers review. Only the headline came through, with no figures. - The one macro-relevant item: MarketWatch ran "The stock market is a hollow tree that could be about to snap, warns bond king Gundlach." Jeffrey Gundlach is warning that equity-market breadth or leadership is fragile. Only the headline came through, with no detail. It is a sentiment signal and not data.

Takeaways for the trader¶

No evidence-based view on COHR is possible from this week's data. I can't support a bullish or bearish call on news flow.
Sentiment risk: The Gundlach warning, a narrow-leadership caution, matters for high-beta, AI-linked technology names. I am not asserting that COHR is such a name or that it trades that way. Check COHR's beta and its correlation to AI-hardware peers.
Critical-minerals theme: Gallium and other critical-mineral supply news is worth watching for COHR's input costs and supply security. Nothing this week shows a direct effect.

Gaps for the next assistant or analyst¶

COHR news from another source, such as press releases, SEC filings or an earnings calendar. The fiscal Q1 report would normally fall in early-to-mid November, but confirm that date.
Fed, rates, inflation and labor data from a source that works. The FRED key is missing.
Price action, technicals and fundamentals for COHR.
The full Gundlach article, for specifics.

Summary table¶

Area	Finding	Status / confidence
COHR company news (9/24–10/1 and 9/1–10/1)	Source unavailable; no items returned	No data (tool limitation)
Fed funds rate	Not retrievable (FRED_API_KEY missing)	No data
10-year Treasury / yield curve	Not retrievable	No data
CPI / inflation	Not retrievable	No data
Unemployment	Not retrievable	No data
VIX	Not retrievable	No data
Prediction markets (Fed cut, recession)	Withheld for 2026-10-01 to avoid look-ahead leakage	No data
Global news: sentiment	Gundlach warns the market is a "hollow tree" that could snap	Headline only; low–medium relevance
Global news: critical minerals	Greenland Mines reports gallium and vanadium additions	Thematic link to COHR; no direct impact shown
Global news: commodities / mining	Small-cap miner releases; Barchart September commodity review	Low relevance
Overall view for COHR	Insufficient evidence to form a directional view	Defer to other data sources

Fundamentals Analyst¶

COHR (Coherent Corp., NYSE) – Fundamental Report, as of 2026-10-01¶

1. Data scope and caveats¶

Profile data was withheld. The get_fundamentals tool returned no market cap, P/E, EV/EBITDA, 52-week range, analyst targets, or sector and industry data. I can't give a valuation view from this data. The conclusions below come only from the financial statements and insider filings.
Fiscal year. The fiscal year ends June 30. The latest column, 2026-06-30, is fiscal Q4 FY26. The vendor doesn't report filing dates, so I can't confirm the quarter was public by 10/1. Coherent normally reports in mid-August, so it probably was.
Data anomalies to treat with caution:
"Diluted NI Avail to Common" for the June 2026 quarter is $275.6M. That is higher than net income of $240.5M and doesn't reconcile with the reported diluted EPS of $1.19. Net income divided by diluted shares gives $1.19, so I rely on that.
"Share Issued" fell from 212.3M to 195.75M in the June quarter, while ordinary shares outstanding were flat at about 195.7M. This looks like a treasury-share or cancellation artifact, not a real buyback.
The equity increase described in section 3 is not labeled in the tool output.

2. Income statement: strong growth, widening margins¶

Quarter ended	Revenue ($M)	Gross margin	Op. income ($M)	Op. margin	Norm. EBITDA ($M)	Net income ($M)	Diluted EPS
Jun-25	1,529.4	35.7%	145.0	9.5%	265.4	-95.6	-0.83
Sep-25	1,581.4	36.6%	172.2	10.9%	311.2	226.3*	1.19*
Dec-25	1,685.6	36.9%	198.6	11.8%	354.6	146.7	0.76
Mar-26	1,805.6	37.7%	226.3	12.5%	387.3	191.4	0.97
Jun-26	2,045.5	38.5%	304.3	14.9%	510.5	240.5	1.19

*The Sep-25 quarter includes a $115M gain on the sale of a business. The Jun-25 quarter includes about $139M of unusual charges.

Revenue momentum.
Revenue grew 33.7% year over year in the June quarter and 13.3% from the prior quarter.
Sequential growth has risen every quarter: +3.4%, +6.6%, +7.1%, +13.3%.
Trailing-four-quarter revenue is about $7.12B.
Operating leverage.
Gross margin expanded about 280 bp year over year, and operating margin expanded about 540 bp.
SG&A was nearly flat (about $245M to $266M) while revenue rose 34%.
R&D is rising (about $216M, or 10.6% of revenue, up from $156M), which points to continued reinvestment.
Profit.
Normalized EBITDA was $510.5M, a 25.0% margin, versus 17.4% a year ago. Trailing-four-quarter normalized EBITDA is about $1.56B.
Operating income more than doubled year over year ($145M to $304M).
Interest and tax.
Interest expense fell from $55–59M a quarter to $41M, after the debt paydown.
The tax rate was erratic: 1.5% in March, 15.2% in June, and a benefit in September 2025. Net income can swing on tax.
Earnings quality.
June had $50M of unusual charges, including a $44M write-off.
Restructuring and acquisition costs fell from $54M to $6M.
Other non-operating income was $65.6M in June, up from $28M in March. This is a non-core item worth checking.
Dilution.
Diluted shares rose from 155.5M to 202.2M, about 30% in a year, mostly from the preferred conversion and an equity raise (section 3).
Even so, diluted EPS recovered to $1.19, equal to the Sep-25 quarter that included a large gain.

3. Balance sheet: recapitalized, but working capital and capex are rising fast¶

Liquidity.
Cash was $1.16B plus $825M of short-term investments, so $1.99B in total. That is down from $2.42B in March.
Current ratio fell to 2.43 from 3.05 in March, and working capital fell from $4.33B to $4.07B.
Leverage.
Total debt is $3.54B, almost all long-term ($3.21B), with little near-term maturity pressure. Debt is down from $3.89B a year ago.
Net debt is $2.06B, about 1.3x trailing normalized EBITDA. That is comfortable.
EBIT covers interest about 7.8x.
Capital structure change.
The $2.5B preferred stock disappeared in the December 2025 quarter and common stock rose by about the same amount, so the preferred appears to have converted.
In the March 2026 quarter, common stock rose another $2.07B. Financing cash flow of +$1.85B that quarter implies a roughly $2B equity raise, even though debt was net repaid. Verify this in the filings.
Stockholders' equity grew from $8.1B to $10.9B.
Tangible book value turned positive, from -$2.0B a year ago to +$3.6B.
Asset base.
Goodwill and intangibles are $7.26B, about 40% of total assets, which leaves impairment risk.
Net PP&E rose 60% in a year, from $1.88B to $3.0B. Construction in progress is $777M, up from $363M, so capacity is being built.
Inventory build.
Inventory is $2.58B, up 80% year over year and 21% from March, while revenue rose 34%.
Days of inventory are about 187, versus about 133 a year ago.
Work in process is $1.56B. That fits a ramp ahead of demand, but it is a watch item if demand slows.
Receivables.
Receivables are $1.34B, about 60 days of sales versus about 57 a year ago, so no major deterioration.
Payables.
Accounts payable jumped from $1.34B to $1.91B in one quarter. Much of this likely reflects capex and inventory purchases, and it temporarily supports cash.

4. Cash flow: heavy investment phase, negative free cash flow¶

Quarter	Operating CF ($M)	Capex ($M)	Free CF ($M)
Jun-25	130.3	-131.4	-1.1
Sep-25	46.0	-103.9	-58.0
Dec-25	57.9	-153.6	-95.7
Mar-26	-93.8	-289.7	-383.5
Jun-26	69.5	-562.9	-493.4

Free cash flow.
Trailing-four-quarter operating cash flow is only about $80M, against net income of about $805M. That is poor cash conversion.
Trailing-four-quarter capex is about $1.1B, so free cash flow is about -$1.03B.
Why conversion is weak.
Working capital consumed $292M in June and $392M in March, mainly inventory (-$484M in June) and receivables (-$142M).
A deferred-tax benefit and non-cash gains on business sales (-$38M to -$45M a quarter) also reduce operating cash relative to earnings.
Capex trajectory. Quarterly capex quadrupled from $131M to $563M in a year. This is the key cash-flow variable: if it persists at this rate, the roughly $2B of cash and investments funds only a few quarters without new financing or an earnings-driven rise in operating cash flow.
Other items.
Stock-based compensation is about $50M a quarter.
Depreciation and amortization is $141M a quarter, rising.
No dividend has been paid since the September 2025 quarter ($11.4M, likely preferred-related).
Asset sales brought in a net $400M in the September 2025 quarter and $51M in March 2026.

5. Insider transactions¶

Recent activity (August–September 2026) is all selling: - Sep 11: Director DiGirolomo sold 5,315 shares at $305.98 (about $1.63M) and gifted 1,279 shares. - Sep 9: Officer Beard sold 500 shares at $309.32. - Sep 2: Director Neal-Graves sold 2,200 shares at $268.42 (about $0.59M). - Sep 1: CTO Eng sold 13,077 shares at about $271–277 (about $3.58M). - Aug 31: Directors Skaggs and DiGirolomo each sold 2,272 shares at about $277 (about $0.63M each). - Aug 18: CFO Luther sold 3,000 shares at $324. She also sold 1,000 on Jul 22 at $306.68, and has sold 1,000–4,000 shares roughly every month since February 2026 (at $217 to $373). - Aug 28: Annual equity grants went to the CEO (30,564 shares), the CFO (8,731), the CTO (17,333) and other officers. These are compensation, not open-market buying.

Longer-term pattern: - Director Xia has made repeated option-exercise-and-sell trades, and director Skaggs has sold in round-number lots (2,000 shares at $130, $140, $150). - Former officer Barbarossa sold about $18M in October–November 2025 at $140–160. - Bain Capital, a former 10% holder, sold 7.5M shares at $143.37 (about $1.08B) on Nov 7, 2025. - The only open-market purchases in the data are two 500-share buys by CEO Anderson (about $52K each) in November–December 2024, near $103–104. They were tiny and are now stale.

Interpretation. - The selling is broad, small relative to holdings, and at prices far above the 2025 levels (about $80–$140), so it is consistent with profit-taking and diversification. - There are no recent open-market purchases, and there is nothing resembling a cluster of large sales by the CEO. - The stock traded at about $373 in May 2026 and about $305–309 in September, roughly 17% below the May print. I only have insider-trade prices, not a full price series. - Insider flow is neutral to mildly negative as a signal. The absence of buying is notable after an increase of about 4x in the stock in 16 months.

6. Key takeaways for traders¶

Operating momentum is very strong. Revenue growth is accelerating (+34% year over year, +13% from the prior quarter), and gross, operating and EBITDA margins have expanded for five straight quarters. Operating income has more than doubled year over year.
Cash generation is the weak spot. Free cash flow was about -$1.0B over the trailing four quarters, driven by a capex surge and a working-capital build. Whether it turns positive depends on capex normalizing and inventory converting to sales. Watch fiscal 2027 capex guidance and inventory turns.
The balance sheet is sound but the cushion is shrinking. Net debt is about 1.3x EBITDA after the equity raise and preferred conversion, but cash and investments fell by about $430M in the June quarter. Goodwill and intangibles are about 40% of assets.
Dilution has been significant, about 30% in a year. Further raises are possible if capex stays high.
Insiders are net sellers into strength, with no meaningful buying.
Valuation is not assessed. The profile data is withheld, so the next step is to pair these fundamentals with price and valuation data. At about $300 a share and about 196M shares, the market cap would be roughly $59B, which is my own estimate from insider-trade prices and not a vendor figure.
Main risks:
An inventory build of about 187 days ahead of demand.
Capex execution.
Non-operating income and tax rate making earnings noisy.
A slowdown after a very steep run.

7. Summary table¶

Category	Key point	Latest data	Read
Revenue	Quarterly revenue	$2,045.5M (+33.7% year over year, +13.3% from prior quarter)	Strongly positive
Gross margin	Trend over 5 quarters	35.7% → 38.5%	Positive
Operating margin	Trend over 5 quarters	9.5% → 14.9%	Positive
Normalized EBITDA	Quarterly	$510.5M (25.0% margin); trailing four quarters about $1.56B	Positive
Net income / EPS	June quarter	$240.5M / $1.19 diluted	Positive; the tax rate is erratic
Share count	Diluted shares	155.5M → 202.2M	Dilutive
Cash and investments	June 30, 2026	$1.99B (down from $2.42B)	Adequate, declining
Debt	Total / net	$3.54B / $2.06B (about 1.3x EBITDA)	Manageable
Equity	Stockholders' equity	$10.9B; tangible book value +$3.6B	Improved after raise and conversion
Intangibles	Goodwill plus intangibles	$7.26B (about 40% of assets)	Impairment risk
Inventory	Level / growth	$2.58B (+80% year over year, about 187 days)	Watch
Operating cash flow	Trailing four quarters	about $80M against about $805M net income	Weak conversion
Capex	June quarter	$563M (about 4x year over year)	Heavy investment
Free cash flow	Trailing four quarters	about -$1.03B	Negative
Insiders	Aug–Sep 2026	Only sales; CTO sold $3.6M, directors and CFO sold smaller amounts	Neutral to mildly negative
Insider buying	Last purchase	500-share CEO buys, Nov–Dec 2024	No recent buying
Bain Capital	Nov 2025	Sold 7.5M shares at $143.37	Overhang largely cleared
Valuation / profile	Market cap, multiples	Withheld by the vendor	Not assessed

II. Research Team Decision¶

Bull Researcher¶

Bull Analyst: # Bull Case for COHR (Coherent Corp.)

I'll start with the thesis, then take on the objections I expect the bear to raise.

The core argument: an operating inflection that is still accelerating¶

The June 2026 quarter is the strongest evidence for this stock:

Revenue was $2.05B, up 33.7% year over year and 13.3% sequentially. Sequential growth has accelerated for four straight quarters: +3.4%, +6.6%, +7.1%, +13.3%. Businesses that are peaking don't look like this.
Margins have expanded for five consecutive quarters. Gross margin went from 35.7% to 38.5%, and operating margin from 9.5% to 14.9%. Normalized EBITDA margin went from 17.4% to 25.0%.
Operating leverage is real. Revenue rose about 34% while SG&A was nearly flat at roughly $245M to $266M. Operating income more than doubled, from $145M to $304M.
Management is reinvesting. R&D is about 10.6% of revenue, up from $156M to $216M a quarter. That is how a company defends a technology lead in AI data-center optics.

The June quarter's normalized EBITDA of $510.5M annualizes to roughly $2.0B, against about $1.56B over the trailing four quarters. The earnings base is growing faster than the trailing numbers show.

The balance sheet was fixed, which many bulls overlook¶

A year ago this was a levered, preferred-encumbered story. Now:

The $2.5B preferred converted to common.
Total debt fell from $3.89B to $3.54B. Net debt is about $2.06B, roughly 1.3x EBITDA, and EBIT covers interest about 7.8x.
Interest expense dropped from $55–59M a quarter to $41M.
Tangible book value went from -$2.0B to +$3.6B.
Bain Capital sold 7.5M shares at $143.37 in November 2025. That overhang is cleared, and the stock is more than double that price.

Technicals support the move¶

I'll be straightforward about this, because the picture is mixed:

Weekly and monthly SuperTrends are both UP, with stops at $255 and $229. The primary trend has a 25% cushion.
Price is above the 10 EMA, 50 SMA and 200 SMA, in bullish order.
October 1 was a +10.9% day on 11.4M shares, about double normal volume, closing near the high ($319.19 against a $323.23 high). That is accumulation, not a fade.
MACD has crossed up (histogram +1.54), RSI is 56.6 with room before 70, and TD-9 shows no exhaustion on any timeframe.
A daily close above $332 flips the final SuperTrend tier and aligns all three.

The weak spot is that ADX is about 7 and the daily SuperTrend is still down. That means this is a breakout attempt, not a confirmed trend. I'd rather concede that now than have the bear surface it as a gotcha.

The bear's likely objections¶

1. "Free cash flow is about -$1.0B and trailing operating cash flow is only about $80M." This is the strongest bear point, and I'd read it differently:

The cash went into growth assets. Capex quadrupled from $131M to $563M a quarter. Net PP&E is up 60%, and construction in progress doubled to $777M. You don't spend that unless you have demand to fill the capacity.
Peak quarterly capex annualizes to about $2.25B, roughly equal to the annualized EBITDA run-rate of about $2.0B. That is a capacity ramp, not a structural hole. If capex normalizes while EBITDA keeps climbing, free cash flow inflects quickly.
The working-capital drag is timing. Payables jumped from $1.34B to $1.91B, which shows the supply chain is gearing up too.

2. "Inventory is up 80% to $2.58B." Revenue accelerated into that build. Work in process is $1.56B, which looks like a ramp, not unsold finished goods. Receivables are about 60 days of sales versus about 57 a year ago, so there is no sign of customers stretching. If demand were softening, receivables would show it first.

3. "Dilution of about 30%." It happened, but most of it came from converting the preferred. The equity raise bought a stronger balance sheet, and EPS recovered to $1.19 on the larger share count. The company is also earning on the new capital: operating income grew about 110% year over year.

4. "Insiders are selling." Look at the pattern. The sales are small, spread across many people, and made at prices far above the $80–140 levels of 2025. The CFO has sold 1,000–4,000 shares roughly monthly since February, which looks like a routine diversification plan and not a signal. Insiders also received large equity grants on Aug 28, so they are net holders. A 4x move in 16 months will produce selling.

5. "Goodwill and intangibles are 40% of assets." That is a fair risk, but impairment is non-cash. The earnings power on top of those assets is rising, with operating margin at 14.9%, which makes an impairment trigger less likely, not more.

The valuation question¶

The fundamentals feed lacked a valuation profile, so I'll be careful. At about $319 and about 196M shares, the market cap is roughly $62B. That is not cheap on trailing GAAP numbers, and I won't pretend otherwise. The bull case rests on the earnings run-rate, which is moving fast, and on the sector backdrop of AI optical demand. A retail post cited about 26x forward P/E, but I can't verify it, so I'm not leaning on it.

Some chatter points to a Bernstein $350 target and a Citi note on optical circuit switching. These came secondhand from StockTwits and are unverified, so treat them as color, not evidence.

Bottom line¶

COHR combines accelerating revenue, five quarters of margin expansion, a repaired balance sheet and a higher-timeframe uptrend. The main risk is cash: capex and inventory are consuming it ahead of revenue, and the roughly $2B of cash and investments is a finite runway. But the income statement says the investment is being absorbed by demand. I'd rather own the company where operating leverage is just starting to show.

I'm curious how the bear sees it. If the main case is cash burn, I'd like to know what capex or inventory figure would change their mind, and why they think demand won't catch up with the capacity being built. Bull Analyst: # Bull Rebuttal: COHR

The bear landed some real hits, so I'll start with what I'm conceding.

Conceded¶

Capex is above EBITDA. June capex of $563M was about 110% of $510.5M normalized EBITDA. My "roughly equal" was loose. I also have no FY27 capex guidance.
The "+110% operating income" flatters. The June 2025 base had about $139M of unusual charges. The sequential +34% is the cleaner number.
"EPS recovered to $1.19" was loose. Sep-25 also printed $1.19, and that quarter included a $115M business-sale gain. June's other income of $65.6M is worth about $0.27 of EPS if it doesn't recur.
Insiders. I can't confirm a 10b5-1 plan, so I shouldn't have called it routine. There is also no recent buying.
Technicals. The Sep 18-21 pop reversed, OBV hasn't made a new high, and ADX is 7. This is a range, not a trend.
Valuation. My own math gives about 32-33x June-annualized EBITDA using diluted shares. That isn't cheap.

Where the bear overreaches¶

1. "Operating cash flow is 14% of EBITDA" is mostly a working-capital story.

Quarter	Reported OCF	Working-capital drag	OCF before WC	% of EBITDA
Mar-26	-$93.8M	$392M	~$298M	~77%
Jun-26	$69.5M	$292M	~$362M	~71%

This is rough. The fundamentals note flags $38-45M a quarter of non-cash gains and deferred-tax drag, so shave several points. Still, before working capital, June FCF was about -$200M, not -$493M. The real question is whether inventory keeps absorbing $300-500M a quarter. That is the bet, and I'll define the falsifier below.

The bear is right that payables reverse. But June working capital was a net $292M drag even after that support. Supplier credit didn't hide the burn.

2. Margins don't fit the "bad inventory" story. Yield problems and channel-stuffing both show up in gross margin. Gross margin has risen five straight quarters, to 38.5%, during the capacity ramp. Operating expenses are also nearly flat. The $44M write-off is unexplained, and I'll flag it as a question. If it was inventory, it was about 1.7% of the balance.

On receivables, the $142M build is almost exactly what 60 days of sales on a $240M sequential revenue increase implies (about $158M). The drift from 57 to 60 days is worth watching, but it isn't distress.

3. The incremental economics are the strongest data in this debate. - Sequentially, revenue rose $240M and operating income rose $78M, a ~32% incremental operating margin. Normalized EBITDA rose $123M, a ~51% incremental margin. - Year over year, normalized EBITDA rose +92%, from $265M to $510M. That excludes the unusual items the bear flagged. - Net PP&E rose about $1.1B while annualized quarterly EBITDA rose about $980M. That doesn't prove causation, since price and mix contributed, but it is not what poor returns on capital look like. - The bear is right that D&A will rise. My rough estimate is that $1.1B of trailing capex on an 8-10 year life adds about $30M a quarter, about 1.5 points of revenue. That is real, but it is smaller than the 280 bp of year-over-year gross margin expansion. The useful-life assumption is mine.

4. The balance sheet was recapitalized, not "fixed" by operations. Debt fell only $350M, and the roughly $2B equity raise is inferred and needs a filing check. But net debt is about 1.3x trailing EBITDA, or about 1.0x June annualized. The $2.5B preferred is gone. The company has debt capacity, so another equity raise is not the only way to fund a year of heavy capex.

The bear's questions¶

FY27 capex. I'm assuming it stays near June's rate, about $2.1B for the year. The thesis doesn't need a step-down. It needs inventory growth to slow and EBITDA to keep rising. Here is my illustrative math, not guidance:

Revenue: FY27 revenue of about $9.3B needs only about 5% sequential growth per quarter. That is below the last four quarters (3.4%, 6.6%, 7.1%, 13.3%).
EBITDA: at a ~26% margin, EBITDA is about $2.4B.
FCF: at roughly 70% conversion before working capital, FY27 FCF is about -$0.4B, or about -$0.7B with another $300M working-capital drag.
Funding: that is still negative, but it is far better than the ~-$1.0B trailing figure and is covered by the $1.99B of cash. The thesis needs FCF to improve and no raise to be required. It does not need FCF to be positive.

Where I stop paying. On $2.4B of FY27 EBITDA, today's EV of about $66.6B (diluted) is about 28x. I'd stop adding at about 30x forward, roughly $345 a share. That's close to the unverified Bernstein target, but I'm not leaning on that, and a sell-side target tells us little anyway.

What would make me wrong: - Sequential revenue growth below about 3% while inventory days keep rising. - Gross margin rolling over. That would be the yield or pricing tell. - Capex guidance rising again without matching revenue. - Payables unwinding while OCF stays near zero.

Bear's price target¶

The bear says $255 is a fairer entry. The stock closed at $264.41 on Sep 3, about a month ago, with the same cash-flow facts on the table. Would the bear have bought it then? If not, $255 is a price, not a fundamental condition. His other three triggers (capex guidance, inventory days, OCF over 50% of EBITDA) are the real ones, and they arrive after the move, probably at the November report.

Execution¶

I'd agree with the bear on one practical point. With ATR at about 6.7% of price and ADX at 7, the weekly stop at $255 is a trend marker, not a risk limit. I'd size small and build in tranches near the 288-298 moving-average cluster. I wouldn't chase into the resistance at 321.5, 327 and 332.

Insider selling in Aug-Sep totals roughly $8M against a ~$62B market cap, and the data shows no CEO sales. That is a lack of conviction signal, not an alarm.

Bottom line¶

Demand is showing up in accelerating revenue, rising gross margin, flat SG&A, 32-51% incremental margins and stable receivables. The weak spot is the cash statement, and it is mostly a working-capital question that the next two quarters will answer. The valuation leaves little room for a miss, so I'd stay bullish with disciplined sizing.

So what is the bear's view of the demand evidence? He has not identified one data point showing demand is being pulled forward. Bull Analyst: # Bull Rebuttal: COHR (Round 3)

Your question¶

If November shows revenue +6% and inventory +15%, I wait. Days would go from about 187 to about 203, and I won't call that a green light. If gross margin also slipped or OCF stayed near zero, I'd cut, because that trips two of my falsifiers. If gross margin held at 38% or better and capex guidance was flat, I'd hold the position and not add.

What I'm conceding¶

1. I'm retiring the 51% incremental EBITDA margin. Normalized EBITDA ran $65M above operating income plus D&A in June. In March the gap was roughly $35-40M smaller, assuming March D&A near $135-140M, which I don't have. Other non-operating income rose about $37M over the same period ($28M to $65.6M). That's probably not a coincidence, though it is my inference. So part of the $123M sequential EBITDA gain is non-operating. I'll stand on the 32% operating-income incremental margin, which you accepted.

On that cleaner base: - June operating income plus D&A is $445M, or about $1.78B annualized. That is about 37x at $319. - My FY27 case is about $2.2B, not $2.4B. That assumes 5% sequential growth, a 32% incremental margin, and D&A rising about $8M a quarter, all my assumptions. It implies about 30x forward at $319.

That's why I'm not adding here. We reached the same place by different routes.

2. Absorption costing is a real mechanism. An inventory build can flatter gross margin, and I can't exclude it from this data. But SG&A went from about 16.0% to 13.0% of revenue, about 300 bp. That is independent of inventory accounting, so operating leverage doesn't rest on the absorption question alone.

3. Supplier credit did lift June OCF. My earlier wording was too strong. Without about $334M from payables and accruals, June OCF would have been negative.

Where I push back¶

1. Your risk/reward compares the wrong things. $345 was where I'd stop adding at 30x on my earlier $2.4B, not a price target. The $255 weekly stop is a trend marker I already said isn't a risk limit. Neither is an expected outcome. A better frame is: - Entering near $295 (the 50 SMA and 10 EMA cluster) puts $345 at +17% and $255 at -13%. - A 25x multiple on a hypothetical FY28 EBITDA of $3.0B (about 20% revenue growth at about 27% margin, my assumption) implies about $360. - The same 25x on FY27's $2.2B implies about $265. The stock is a bet on growth continuing, and that's the real disagreement.

2. Your capex trigger can't tell us anything. You'd turn constructive if capex were guided down. A lower capex guide fits a company that has finished building and has strong demand, and it fits a company whose demand is softening. Both worlds satisfy it. The better test is whether inventory growth falls below revenue growth while gross margin holds.

3. Financing is the right risk, but it doesn't force a raise. Here is the worst case, using your inventory math: - Inventory: +$0.55B. - Receivables at 60 days on Q4 revenue: about +$0.3B. - Payables offset: zero. - Capex at $2.1B and OCF before working capital at 70% of $2.2B EBITDA.

That gives FY27 FCF of about -$1.4B, which leaves about $0.6B of the $1.99B in cash. Net debt would be about $3.5B, or about 1.6x $2.2B EBITDA. A realistic case has payables growing with COGS and a smaller burn, with leverage around 1.4x. Either way it's tight, and you're right that dilution is the cost of being wrong. But the balance sheet could take debt financing without distress.

4. "No catalyst, so multiple expansion" is an inference from a broken tool. The news report says the missing items are a tool limitation, not an absence of news. The one thing we do have is a one-day StockTwits snapshot, and it points to a sector move. It shows optical names rallying together, including a LITE breakout. That is different from a COHR-specific re-rating. It's also a crowding risk, and I'll concede that. The 20x row in your table isn't derived from peers either, so I'd keep it as a stress case.

5. The absorption claim is testable. If inventory growth drops below revenue growth next quarter and gross margin holds at 38% or higher, absorption wasn't carrying the margin. If gross margin falls as the build stops, you were right. I'll accept that result in either direction.

Where we stand¶

We agree on the business: strong operating leverage, a weak cash statement, and a price that leaves little room for error. We differ on whether to hold a small position while waiting for evidence, or wait for $255-265. At $319 I'm not adding. I'm holding a small position and adding near $295 if the November numbers pass the tests above.

My question back: if November shows inventory growth below revenue growth, gross margin at 38% or better, and OCF above 50% of EBITDA, but capex guidance flat, would you go neutral at $319? Or do you need the price to fall as well? Bull Analyst: # Bull Rebuttal: COHR (Round 5)

Your question: why 25x and not 20x?¶

I can't defend 25x as a derived number. I have no peer multiples, and you don't either. So I'll use a range instead of a point estimate. I'm putting both multiples on FY28 EBITDA of $3.0B and using your year-end net debt of about $3.2B, the midpoint of your $2.8-3.5B range, on 202.2M diluted shares:

FY28 multiple	Implied price	vs. $319	vs. $295
20x	~$281	-12%	-5%
22.5x	~$318	0%	+8%
25x	~$355	+11%	+20%

The market already pays my midpoint. At $319 the stock trades at about 22.5x my FY28 case, with no margin of safety. That is why I'm not adding.
Why I put the top end at 25x and not higher. Growth is decelerating on revenue, but EBITDA growth on my path is still about 36% from FY27 to FY28. That is an argument, not evidence. The multiple has to compress if the growth doesn't show up.
Why I put the bottom end at 20x. A company still burning cash with unproven incremental returns shouldn't get much below that if EBITDA is compounding at 30%+. That is also my judgment.
Why $295 is my add point. It is about 20.6x FY28, the bottom of my range. That makes the skew about +20% against -5% (4:1), versus roughly 1:1 at $319. So I add at $295 and only hold at $319.

What I'm conceding¶

The net-debt correction. You're right that year-end FY27 net debt is the correct input, and it takes about $5 off my $360 figure.
My $3.0B for FY28 is a bit generous. On the observed 32% operating incremental margin, plus D&A rising about $130M, FY28 EBITDA comes out nearer $2.9B. That is about $11 a share at 22.5x. Each turn of multiple on $3.0B is about $15 a share.
The inventory test is a partial pass. Inventory growth below revenue growth only stops days from rising. A stricter test is inventory days heading back toward the 160s or lower by the following quarter.
FCF after capex is the better test than OCF. On flat capex of about $525M a quarter, my FY27 EBITDA path gives Q1 FCF of roughly -$185M at 70% OCF conversion, or -$280M at your 50%. FCF only gets to about breakeven in FY28. I'm not claiming the burn ends this year.

Where I still push back¶

1. Payables don't change my worst case. I agree payables days jumped from about 107 to 138 in one quarter, and capex payables are mixed in. But my worst case already assumed zero payables offset. At 120 days on Q4 FY27 COGS of about $1.53B, year-end payables would be about $2.0B, roughly flat to up $0.1B from today's $1.91B. The reversion would only hurt if it happened immediately, and that would be a timing hit against $1.99B of cash, not a change in the full-year conclusion.

2. The real swing factor is growth. Our disagreement isn't about 20x versus 25x. It's about my 5% sequential growth assumption for FY27, which is already well below the four-quarter pattern of +3.4%, +6.6%, +7.1% and +13.3%. - If the 7.6% four-quarter average continued, FY27 revenue would be about $9.9B and EBITDA about $2.4B, roughly $0.2B above my case. - At 22.5x on FY28, that is worth roughly $20 a share or more. It would also come with higher capex, so FCF wouldn't improve one-for-one. - If growth falls to 3%, with inventory still rising, the numbers go the other way. - That is the actual bet. November will tell us a lot about which path we're on.

3. Multiple compression is a risk, but so is the denominator. You're right that deceleration usually brings de-rating. But on my numbers, FY27 EBITDA is about 24% above the June run-rate. A stock that goes sideways for a year while EBITDA grows 24% de-rates from about 36x to about 29x, which is compression without a price decline.

Where we land¶

We agree on almost everything factual: real operating leverage, a weak cash statement, a price with no margin for error, and no case for chasing.

The difference is small. You'd stay bearish at $319 until cash conversion improves, and go neutral on a clean November. I'd hold a small position and add only near $295.
Why I hold at all. Operating leverage has been beating expectations, as revenue acceleration shows. The cost of being out is a $2.4B-EBITDA outcome that the market would pay up for.
What would change my view. At 22.5x with no cushion, I'd trim if November shows revenue growth under 3% with inventory days still rising, gross margin below 38%, or payables unwinding with OCF near zero.
What would make me add above $300. Inventory days falling toward the 160s, gross margin holding at 38% or better, OCF above 50% of EBITDA, and capex growth below revenue growth. I'd treat that as evidence that the capacity is being absorbed, which is the thesis.

Everything here rests on my own estimates from the financial statements, with no valuation data from the vendor, no peer multiples, no guidance and no verified catalyst for the 10.9% day. The November report date is unconfirmed.

Bottom line: I'm bullish on the business and neutral on the stock at $319. It's a hold with a defined add point and defined exit triggers.

One question back: if November passes every cash test but the stock has drifted to $345, would you still wait for $265, or does the evidence move your entry? Bull Analyst: # Bull Rebuttal: COHR (Final Round)

Your question¶

$319 at 20x on $2.5B is about $230, or -28%. Your math checks out: $50B EV, less ~$3.5B year-end net debt, over 202.2M shares. Against today's EV of about $66.6B, $2.5B of EBITDA is about 26.6x. My table omitted a miss row, and that was a real omission.

Would I hold at $230? It depends on how it got there. - Tripwires tripped (revenue growth under 3%, gross margin under 38%, or inventory days still rising): I'd be out before $230. The tripwires exist so I'm not holding through a confirmed miss. - Tripwires intact, $230 from sector beta or de-grossing: that is about 17x my corrected $2.9B FY28 case, and I'd add.

So the price alone doesn't decide it. What the November print says does.

What I'm conceding¶

My 4:1 skew was conditional. It paired a low multiple with high EBITDA, which is the one combination a miss rules out. Your correlated version is the fairer test.
Your weighted values are arithmetically right. 25/50/25 gives about $300, and 35/50/15 gives about $312.
Your $230 miss case is arguably too mild. My own tripwire case is 3% sequential growth, which puts FY27 EBITDA near $2.0B, not $2.2B. FY28 would then be about $2.3B at 18x, or roughly $185. At 16x on $2.5B, it's about $180. The downside tail is fatter than your table shows.
"Beating expectations" isn't in the data. I have no consensus, guidance or backlog, so I'm dropping that line.
Your hurdle point is fair. The table is a mid-2027 value, so a 6-7% cost of equity applies.

Where I push back¶

Your table lacks an upside row too. The 7.6% four-quarter average growth path gives FY27 EBITDA near $2.4B and FY28 near $3.3B, my rough extrapolation. At 25x and ~$3.2B net debt, that's about $392, or +23%. Here are four scenarios with weights that are my judgment:

Scenario	Mid-2027 price	Weight
Strong ($3.3B, 25x)	~$392	15%
Top ($3.0B, 25x)	~$355	25%
Base ($2.9B, 22.5x)	~$307	40%
Miss ($2.5B, 20x)	~$230	20%

The weighted value is about $316, which is -1% from $319 and +7% from $295. This does not contradict you. We both find no edge at $319 and some edge in the $290s. The disagreement is $319 versus $295, and the weights are soft enough that neither of us can claim precision. Moving 10 points of weight between the top and miss cases swings the answer by about $12.

Where this leaves me¶

Against a 6-7% hurdle, $319 earns slightly less than nothing on my own weights. "Hold small" doesn't hold up as an argument for the stock. It only holds up as a sizing choice under uncertain inputs. So I'll tighten my position:

Hold only tracking size. That means a position where a -28% outcome costs well under 1% of the portfolio. I would not carry a full position into November at $319.
Add near $295 or on evidence. The evidence would be inventory days falling toward the 160s, gross margin at 38% or better, OCF above 50% of EBITDA, and capex growth below revenue growth.
Exit on the tripwires. These are revenue growth under 3% with inventory days still rising, gross margin under 38%, or payables unwinding with OCF near zero.

Bottom line¶

We agree on the facts: - Operating leverage is real. The incremental operating margin is about 32%, and SG&A fell from about 16% to 13% of revenue. - The cash statement is weak. Trailing FCF is about -$1.0B, and June OCF was positive only because of roughly $334M from payables and accruals. - There's no margin of safety at $319. The valuation already prices a good FY27 and a strong FY28. - The swing factor is growth. Whether FY27 growth is closer to 3%, 5% or 7.6% per quarter decides the outcome far more than the choice between 20x and 25x.

I'm bullish on the business and neutral on the stock at $319. The bear's case for patience is stronger than my case for holding, and my position size should reflect that.

All of this rests on my own estimates from the financial statements. There's no vendor valuation data, peer multiples, guidance or verified catalyst for the 10.9% day. The November date is unconfirmed, and the Citi, Bernstein and Morgan Stanley items are secondhand.

One question back: if COHR is at $290-295 into the print, before any evidence, would you buy a starter position? Or does your "wait for the cash tests" rule apply at that price too?

Bear Researcher¶

Bear Analyst: # Bear Case for COHR

The bull deserves credit for conceding the cash burn and the ADX problem up front. The June quarter was strong, and I'm not disputing the revenue. But his concessions are bigger than he treats them, and several of his rebuttals don't hold up against his own numbers.

1. His capex math is the bear case¶

The bull says annualized capex of about $2.25B is "roughly equal" to annualized EBITDA of about $2.0B, so it's a ramp and not a hole. But $2.25B is more than $2.0B. In the June quarter, capex of $563M was about 110% of normalized EBITDA of $510.5M. That is a company spending more than it earns before interest, taxes and working capital.

"If capex normalizes" carries his whole thesis, and nothing in the data shows it. The path is 131 → 104 → 154 → 290 → 563, which looks like acceleration, not a peak. I have no FY27 capex guidance.
"Timing" doesn't explain five straight quarters. Operating cash flow as a share of normalized EBITDA was about 49%, 15%, 16%, negative and 14%. Trailing operating cash flow is about $80M against about $805M of net income.
Payables jumped about $570M in one quarter. The bull reads that as supply chains gearing up. The fundamentals note says it likely reflects capex and inventory purchases. That is supplier financing, and it reverses when the bills are paid.

2. The balance sheet was fixed by issuing stock¶

Total debt fell only about $350M, from $3.89B to $3.54B. Financing flows imply a roughly $2B equity raise, which still needs checking in the filings. Most of that money funded the burn, not deleveraging.
The tangible book swing from -$2.0B to +$3.6B comes from the preferred conversion and the raise, not retained earnings.
Cash and investments fell about $430M in the June quarter alone, to $1.99B. At June's free cash flow of -$493M, that is about four quarters of runway, with capex still rising.
Diluted shares are already up about 30%. If the burn continues, the easiest way to fund it is another raise.

3. Inventory is outrunning revenue¶

Inventory days are about 187 versus 133 a year ago. Inventory rose 21% sequentially while revenue rose 13%, and it absorbed $484M of cash in June. The bull calls the $1.56B of work in process "a ramp." But about 60% of inventory sits in WIP, and WIP is also where yield problems and component bottlenecks accumulate. The data can't tell those apart. I'd also like to know what the $44M write-off in June was. Receivables days moved from 57 to 60, and receivables consumed $142M of cash. The bull sees stability, but the drift is in the wrong direction.

4. Earnings quality is softer than the headline¶

The "+110% operating income" compares against a June 2025 base with about $139M of unusual charges. Sequentially, operating income rose about 34%, which is still strong but a different story.
Other non-operating income was $65.6M, about 22% of operating income, versus $28M in March. If it isn't recurring, my estimate is that about $0.27 of the $1.19 EPS came from it, after a 15.2% tax rate.
The tax rate was 1.5% in March and 15.2% in June.
The bull says EPS "recovered to $1.19." The Sep-25 quarter also printed $1.19, and that one included a $115M gain on a business sale.
Capex is about 4x D&A of $141M a quarter. As that spend goes into service, depreciation will rise and press on the gross margin expansion the bull is counting on. This is my inference, not a reported figure.

5. Valuation: the bull acknowledged it and moved on¶

The vendor withheld valuation data, so these are my own calculations. At $319.19 and about 196M shares, market cap is about $62.5B. Adding $2.06B of net debt gives an EV of about $64.6B.

Metric	Multiple
TTM normalized EBITDA ($1.56B)	~41x
June annualized EBITDA ($2.04B)	~32x
TTM revenue ($7.12B)	~9x
TTM GAAP EPS (~$4.11)	~78x

The retail 26x forward P/E, if accurate, implies about $12 of EPS, roughly three times trailing GAAP. That is what's priced in, and free cash flow is -$1B. Even the bull's unverified Bernstein $350 target is only about 9.6% above the current price. The weekly SuperTrend stop at $255.29 is about 20% below it. That is a poor risk/reward even using the bull's own source.

6. The technicals are weaker than presented¶

We just saw this pattern. On Sep 18 the stock rose 7.2% on 10.16M shares. It reached 321.52 on Sep 21 and fell 9.6% to 290.61 by Sep 24. Today's 319.19 close is still below that failed high.
Confirmation is missing. OBV is 303.6M against a 312.3M peak, ADX is 7, and the daily SuperTrend is DOWN with its stop at 332.01. There is also a stack of resistance at 321.5, 327 and 332.
The catalyst is unknown. No news source worked, so a +10.9% day has no verified explanation. The Citi and Bernstein items are secondhand StockTwits posts.
A 25% cushion isn't protective here. The stock fell from 426.89 on Jun 2 to 222.05 on Jul 29, a 48% drop in eight weeks. It then rose about 71% to 379.13 by Aug 7 and fell about 30% to 264.41 by Sep 3. ATR is about 6.7% of price per day, and the technical report itself calls trend signals unreliable at ADX 7.

7. Insiders¶

The Aug 28 grants are annual compensation, not buying. They don't make insiders "net holders" in any sense that matters. Every open-market transaction in the data from August to September is a sale, including the CTO's $3.6M. The CFO has sold monthly since February, and I see nothing in my data confirming a pre-arranged plan. The only open-market buys were two 500-share CEO purchases of about $52K each in late 2024. I agree this isn't alarming by itself. But nobody who sees the order book bought after a 4x move.

I'm setting aside goodwill (40% of assets) as secondary, and customer concentration as unquantified. A retail post claims heavy hyperscaler exposure, but it's unverified.

What would change my mind¶

You asked for specifics:

Capex: FY27 guidance stepping down toward the March run rate of about $290M a quarter or lower, with operating cash flow above about 50% of EBITDA.
Inventory: days falling back toward the 130s without write-downs.
Price: a pullback toward the $255 weekly stop, which I'd call a fairer entry for a business burning about $0.5B a quarter.

The next test is the fiscal Q1 report, normally early-to-mid November (unconfirmed). It will show whether capex and inventory kept climbing.

Bottom line¶

I'm not arguing demand fails. I'm arguing that at about 32–41x EBITDA the stock is priced for flawless execution, and the cash statement leaves no margin for error. If hyperscaler spending pauses, COHR is left with $2.58B of inventory, $3.0B of net PP&E, $777M of construction in progress and about $3.5B of debt. The same operating leverage then works in reverse. My stance is bearish until the cash conversion shows up.

What FY27 capex number are you assuming, and at what EBITDA multiple do you stop paying? Bear Analyst: # Bear Rebuttal: COHR

You made real concessions, so I'll make mine first. The incremental margins are genuine: about 32% at the operating line and about 51% on normalized EBITDA. Receivables don't concern me, and the $8M of insider selling is directional, not alarming. I'm also not arguing solvency. Net debt of about 1.0-1.3x EBITDA isn't a distress case.

My argument is about price versus cash conversion. Your closing message supports it more than you seem to realize.

1. Your execution plan is my thesis¶

You would size small, build in tranches near the 288-298 moving-average cluster, and not chase into 321-332. You'd stop adding at about $345. That is a plan to buy lower, which is what I said.

Using your own levels:

Upside to your stop-paying price: $345 is about +8%.
Downside to the weekly SuperTrend stop: $255.29 is about -20%. The July low of $222.05 is about -30%.

Giving up 20-30% to make 8% is not a "stay bullish" setup. The only gap between your entry and mine is $290 versus $255, and even that is partly about how you treat a weekly stop you agree is "a trend marker, not a risk limit."

2. Would I have bought at $264.41 on Sep 3?¶

Yes, as a small starter position, and it's consistent with my view. Price is a fundamental condition because it sets the multiple. I use your $2.4B FY27 EBITDA and a 202.2M diluted share count:

Price	EV / June-annualized EBITDA ($2.04B)	EV / your FY27 EBITDA ($2.4B)
$227	~23.5x	~20x
$264.41 (Sep 3)	~27x	~23x
$319.19 (now)	~33x	~28x
$345 (your ceiling)	~35x	~30x

The stock rose about 21% in four weeks with no verified fundamental catalyst in the data. The news tools were down, and the Citi and Bernstein items are secondhand posts. I read that as multiple expansion, not new information. A stock that fell 48% in eight weeks (Jun 2 to Jul 29) and then rose 71% in the next nine (Jul 29 to Aug 7) is priced on sentiment, not anchored to cash flow.

On the 20x row: it is illustrative and not derived from peer multiples, which I don't have. But if FY27 EBITDA lands exactly where you say and the market pays 20x for a company still burning cash, that is about $227.

3. "Before working capital" removes the business¶

Your table shows OCF before working capital at about 71-77% of EBITDA. But inventory is 187 days of COGS, and a company growing this fast on that cycle will keep absorbing cash. Excluding working capital here is like excluding COGS.

Two points of arithmetic from your FY27 case:

Inventory: at your 5% sequential growth and a flat 38.5% gross margin, Q4 FY27 COGS is about $1.53B. Holding 187 days requires about $3.1B of inventory, roughly $0.55B more cash tied up. Getting back to about 150 days requires inventory to stay flat for four quarters while revenue grows about 21%. Your $300M working-capital drag has little room in it, before any payables offset.
June OCF: inventory and receivables absorbed $626M, and the net working-capital drag was $292M. So roughly $334M came from payables and accruals. I can't split supplier credit from accruals or customer advances with this data, so that figure is rough. But without it, June operating cash flow of $69.5M would have been about -$265M. You said supplier credit "didn't hide the burn." It did turn a negative quarter positive.

Some of the $570M payables jump probably also funds capex. That is my inference, since the data doesn't label it. If so, true cash capex is higher than the $563M reported once those bills are paid.

4. Rising gross margin doesn't clear the inventory¶

You say yield problems and channel-stuffing would show up in gross margin. There are two reasons they might not:

Absorption costing. Building inventory faster than you sell it (+21% sequentially versus +13% revenue) capitalizes fixed manufacturing overhead into inventory instead of expensing it. Rising gross margin during an inventory build is what that mechanism produces. I can't prove it from this data, but it means margin can't exonerate the build.
The write-off. The $44M write-off sits in "unusual charges," and normalized EBITDA adds those back. I can't see where it was booked. Your 51% incremental EBITDA margin depends on the normalized figure. Normalized EBITDA of $510.5M exceeds operating income plus D&A ($304M + $141M) by about $65M of add-backs. About $50M is identified as unusual items, and I can't identify the other $15M.

5. The returns-on-capital comparison is selective¶

You compare net PP&E up $1.1B with annualized EBITDA up $980M. That excludes the roughly $1.15B inventory increase (my estimate, from the 80% growth). It also credits that EBITDA to capital that wasn't there yet. Construction in progress is $777M and not producing. The $563M June quarter has had no time to earn anything.

Capex went from about 8.6% of revenue to about 27.5% in a year. That is a different business model from the one that produced those margins. I'm not saying the returns are bad. I'm saying they're unproven, and you are paying 28x forward for the proof.

6. The demand question¶

You say I haven't shown one data point of pull-forward. I'm not claiming pull-forward. I'm saying neither of us can tell, because this dataset has no backlog, no book-to-bill, no guidance and no customer concentration. Revenue is the output we're trying to forecast, so it can't also be the proof.

The data points that do exist are the inventory days, up 54 days in a year, the supplier-funded cash flow, and the unexplained write-off. None is damning alone. Together they say the company is carrying more of the demand risk on its own balance sheet.

Bottom line¶

I'm bearish at $319, not bearish on the business. Your plan and mine agree on the key point: this isn't a level to chase. The ceiling is about $345, the floor is about $255 or lower, and the cash statement is the weak link. I'd move to neutral on a pullback toward $255-265. I'd turn constructive on the November report if it shows capex guided down, inventory days falling, and OCF above half of EBITDA. A stronger revenue print alone wouldn't do it.

My question: if the November report shows revenue up 6% but inventory up another 15%, is your next move to add or to wait? Bear Analyst: # Bear Rebuttal: COHR (Round 4)

Your question¶

Yes, if November shows inventory growth below revenue growth, gross margin at 38% or better, and OCF above 50% of EBITDA, I go neutral at $319. I wouldn't need the price to fall for that. Those tests remove my cash-conversion thesis, and I'd say so.

Neutral isn't constructive, though. With capex flat near $525M a quarter, even a passing print leaves FCF negative:

On your FY27 path, Q1 EBITDA (operating income plus D&A) is about $485M, so 50% conversion is about $245M of OCF.
Against about $525M of capex, that is about -$280M of FCF a quarter, roughly -$1.1B annualized. That is the same burn as the trailing year.

So the tests would show the burn is financed by growth and not by a deteriorating business. They wouldn't show it ending. I'd get constructive when capex intensity falls, meaning FCF after capex improves quarter over quarter. You're right that a capex guide alone can't tell us that.

What I'm conceding¶

Capex guidance is ambiguous. A lower guide fits finished-and-strong or softening-demand equally well. FCF after capex is the better test.
I'm retracting part of my June-2025 base point. I called the +110% operating income growth flattered by $139M of unusual charges. But Jun-25 normalized EBITDA of $265M is about equal to operating income of $145M plus D&A. D&A for Jun-25 is my estimate at about $120-130M, since I only have June 2026 at $141M. That means most of the $139M likely sat below the operating line. The sequential +34% is still the cleaner number, but the year-over-year margin expansion is probably more real than I said.
SG&A leverage is real. SG&A fell from 16.0% to 13.0% of revenue, which is about 300 bp of the 540 bp operating margin gain. The other 280 bp is gross margin, which is the part absorption costing could flatter. The two-part split is fair to you.
My "multiple expansion" read leaned on a broken tool. The StockTwits snapshot shows a sector-wide optical move, including a LITE breakout, not a COHR re-rating. I'd now call it crowded sector beta, and you conceded the crowding risk.
Solvency isn't in question. Your worst case leaves net debt at about 1.6x EBITDA. That is dilutive or costly, not distressing.

Where I still disagree¶

1. Your $360 target uses the wrong net debt. The FY28 case is 25x on $3.0B, which gives an EV of $75B. Subtracting today's $2.06B of net debt gives about $360 a share. But your own FY27 case burns $0.7-1.4B. Using the year-end net debt of about $2.8-3.5B gives about $354-357. That is +11-12% from $319, before any further dilution.

The case needs about 20% growth after 30%, and about 320 bp more margin than your FY27 case. Your downside, 25x on FY27's $2.2B, is about $265, or -17%. Neither of us has peer multiples, so the 25x is an assumption on both sides.

Entry	Your upside case (~$355)	Your downside case ($265)
$319	about +11%	about -17%
$295	about +20%	about -10%

Your $295 add point is where the stock was on Sep 30, at $287.81. We aren't arguing about the business. We're arguing about whether $319 is a price worth holding at, or one to wait out.

2. "Payables grow with COGS" starts from an inflated base. - June payables were $1.91B against COGS of about $1.26B, which is about 138 days. - March payables were $1.34B against COGS of about $1.12B, which is about 107 days. - That is a 31-day stretch in one quarter. It's rough, because capex payables are mixed in, and I can't split them. - If payables revert even to about 120 days, that is roughly a $250M outflow (about 18 days on $1.26B of quarterly COGS) that your "realistic case" doesn't include.

If capex stays high, those capex payables stay high too, so the reversal depends on capex timing. That's why I'd watch it.

3. The inventory test has a low bar. Inventory growth below revenue growth only stops days from rising. It doesn't bring 187 days down toward the 133 of a year ago. I'd count that as a pass, but a partial one.

Bottom line¶

We've converged on the facts. The operating leverage is real, the cash statement is the weak link, and neither of us wants to chase. I hold a bear stance at $319 because the price needs about 30x your own FY27 EBITDA to be justified, and the upside case needs growth to stay near 20% on top of 30%. I'd go neutral on a clean November print, and constructive once FCF improves, not only OCF.

My question for you: your FY27 case decelerates from 34% to about 30% growth, and your FY28 case to about 20%. What multiple do you expect the market to pay as that deceleration shows up in reported numbers, and why is 25x the right answer and not 20x? Bear Analyst: # Bear Rebuttal: COHR (Round 5)

Your question¶

At $345 after a clean November, I would not buy. Passing the tests moves my entry up, but not that far.

A clean print cuts the weight on my downside case, so my entry moves from the mid-$260s to somewhere in the $280s-$295. That is your add zone, so we converge there. It doesn't reach $345 because a pass is already in the price by then. Your own table puts the mid-2027 value at about $307-318 if FY28 EBITDA is $2.9-3.0B at 22.5x. That is 8-11% below $345. If the stock gets there on the print, I wait or pass.

What I'm conceding¶

Payables. At 120 days on Q4 FY27 COGS of about $1.53B, payables are about $2.0B. Your worst case assumed zero payables help, so a slow reversion is a timing risk and not a full-year hole. I'm dropping the $250M outflow as a standalone argument.
Growth is the swing factor. The gap between 5% and 7.6% sequential growth is worth far more than 20x versus 25x. We agree that's the bet.
The entry gap is small. $295 versus $265 is about 1.4 ATRs. The real disagreement is whether to carry a position into a binary November print at $319.
A minor correction. $295 is about 21x your $3.0B FY28 case, not 20.6x, and about 21.7x on your corrected $2.9B.

Where I still push back¶

1. The table is a mid-2027 price, not today's. You subtract year-end FY27 net debt, so each row is the value when FY28 becomes the next-twelve-months year. That's 8-9 months away. Reading 0% at the midpoint and +11% at 25x as "return" means roughly 0-11% over that window. A cost of equity of 8-10% a year is about 6-7% over it (my assumption). So the midpoint row earns nothing for the risk.

2. The 4:1 skew pairs a low multiple with a high EBITDA. Your -5% at $295 puts 20x on your $3.0B, which is the case where growth showed up. Multiple and EBITDA are correlated, so a miss would hit both. Here is the version with correlated scenarios:

Scenario	FY28 EBITDA	Multiple	Year-end net debt	Mid-2027 price	vs $319	vs $295
Your top	$3.0B	25x	$3.2B	~$355	+11%	+20%
Base (your corrected)	$2.9B	22.5x	$3.2B	~$307	-4%	+4%
Miss	$2.5B	20x	$3.5B	~$230	-28%	-22%

The $2.5B miss case is my assumption, about 14% growth over your FY27 case with a larger burn. With illustrative 25/50/25 weights, the expected price is about $300. That is -6% from $319 and +2% from $295. Even at 35/50/15 it's about $312, or -2% from $319. You need the optimistic tail to be both likely and cheap, and at $319 it is neither.

3. A range centered on the price will always say "fairly priced." You say the market pays your midpoint at $319. But 20x and 25x are your judgment, with no peer data, and 22.5x is exactly where the stock sits. That tells us the range is consistent with the price, not that the price is right.

4. "Beating expectations" isn't in the data. We have no consensus estimates, guidance or backlog. Revenue acceleration is not evidence of a beat. June's +13.3% quarter is also nearly half of the four-quarter sum of growth, and it came with inventory up 21% and a $570M payables jump. I can't tell whether it is run-rate or lumpy. Neither can you, and your 7.6% average leans on it.

5. The de-rating math assumes a flat stock for a year. Going from 36x to 29x without a price decline requires COHR to go sideways while EBITDA grows 24%. This stock fell 48% in eight weeks, rose 71% in nine, and fell about 30% in four. Daily ATR is 6.7%. The multiple will not glide down on a schedule.

6. The print is asymmetric into November. The stock rose 10.9% in one day on a sector move that you and the StockTwits snapshot both describe as crowded, with visible profit-taking at $319. A clean print is the base case in the price, so I'd expect a modest reaction. A miss on inventory, gross margin or capex guidance would get a larger one. That's a reason to size small, which you already do, and to wait for the evidence at this level.

Where we land¶

We agree on the business and on the cash tests. We disagree on one decision: whether a small position at $319 earns its keep through a binary print.

My stance: bearish at $319, neutral on a clean November, constructive once FCF after capex improves. After a clean print I'd buy in the $280s-$295 range, not at $345.
What would change my mind faster: November showing revenue growth near or above your 7.6% average with inventory growth below revenue growth. Gross margin at 38% or better and OCF above 50% of EBITDA on top of that would nearly do it. FY27 capex guided at or below about $2.1B would complete it.
What would make me more bearish: inventory days above 200, gross margin below 38%, or any equity raise.

Everything here still rests on my own estimates from the financials. We have no vendor valuation data, no peer multiples, no guidance and no verified catalyst for the 10.9% day. The November date is unconfirmed.

My question back: your table has no row where FY28 EBITDA misses, but your own tripwires (revenue growth under 3%, gross margin under 38%) describe that case. What does $319 look like at 20x on $2.5B, and would you still hold the position at $230? Bear Analyst: # Bear Closing Rebuttal: COHR

Your question¶

At $290-295 into the print, before any evidence, I would not buy a starter. My rule isn't "wait for cash tests at any price." It's that the price has to pay me for the binary event, and $290-295 doesn't. A tracking-size starter in the $265-275 range is where I'd act without waiting.

Using your own four-scenario table:

The miss row is stale. You said the tripwire case is nearer $180-185, but the $316 weighted value still uses $230. If half the miss weight moves to $185, the weighted value is about $312. If all of it moves, it's about $307.
Returns vs. your hurdle. From $295, $307-316 is +4% to +7% over 8-9 months, against the 6-7% hurdle you accepted. That is no excess return, not "some edge in the $290s."
Where the edge starts. For about +15%, a hurdle plus a risk premium, I need an entry of about $267-275. That is the $265 level I named in round 1, now supported by your weights.
Model noise. You said moving 10 points of weight swings the answer by about $12, or about 4% of $295. The edge at $295 is smaller than the error in the model. A decision whose edge is inside the noise should wait for information, and the print is information.

What I'm conceding¶

Waiting has a cost. If November is clean and the stock gaps up, I pay $320+ instead of $295. I argued that a clean print is largely priced and would draw a modest reaction. If that's wrong, you're right to hold a starter. I can't have it both ways, and the cost of being wrong is real.
The weighted-value arithmetic. $316 is right on your weights.
"Bullish on the business, neutral on the stock" is a real move. It's close to my position.
The exit discipline is a good rule. The tripwires are specific and testable.
A tracking position is a defensible sizing choice. I'd only disagree on how small it should be, below.

Where I still push¶

1. "Out before $230" overstates what a tripwire gives you. Your tripwires are read from a quarterly report, so the stock reprices first. COHR has fallen 9.6% in three sessions (Sep 21-24) with no verified news, and 48% in eight weeks. With ATR at 6.7%, a bad print can gap through the level you intended to exit at. I can't size that gap from this data, but it means the realistic tail is worse than the rule suggests.

2. "Tracking size" should be smaller than it sounds. If a miss takes the stock to $185 (-42%), a loss of "well under 1%" of the portfolio means a position of about 2% or less. At $230 (-28%) you'd have room for about 3%. Sizing to the fat-tail case is the discipline your own concession implies.

3. The "strong" row leans on one quarter. The 7.6% average is lifted by June's +13.3%. Excluding June, the other three quarters average about 5.7%, close to your 5% base. I see no way to know whether June is run-rate or lumpy, since the same quarter had inventory +21% and a $570M payables jump. A 15% weight on repeating June at 25x is generous, though I'd accept 10% and see little change in the conclusion.

4. The pullback itself carries information. Yesterday's close was $287.81, so $290-295 is simply the pre-rally level. The stock gets there by giving the whole October 1 gain back. Given the sector-beta and crowding evidence we both cited, that more likely means the optical trade is unwinding than a clean entry opening up.

Where we land¶

We now agree on the facts and nearly on the decision.

Facts we agree on: - Operating leverage is real: a 32% incremental operating margin, and SG&A down from about 16% to 13% of revenue. - The cash statement is the weak link: about -$1.0B of trailing free cash flow, with June OCF positive only because of roughly $334M from payables and accruals. - At $319 there's no margin of safety. - Growth is the swing variable, not the 20x vs. 25x debate.

My stance: bearish at $319, meaning underweight or avoid, not a short on a business I think is improving. - Constructive triggers: - Inventory growth below revenue growth, with days heading toward the 160s. - Gross margin at 38% or better. - OCF above 50% of EBITDA. - FCF after capex improving quarter over quarter. - Entry: $265-275 with no evidence needed. In the $280s-$295 after a clean print. - More bearish on: inventory days above 200, gross margin below 38%, or any equity raise.

Limits of this analysis: every valuation figure is my own estimate from the financial statements. There is no vendor valuation data, peer multiples, guidance, or backlog. The catalyst for the 10.9% day is unverified, the November report date is unconfirmed, and the Citi, Bernstein and Morgan Stanley items are secondhand StockTwits posts. A small position held for sizing reasons is an honest answer to that uncertainty. At $319, though, I wouldn't pay for it.

Research Manager¶

Recommendation: Underweight

Rationale: By the final round both sides agreed on the facts, and the bull conceded the bear's case for waiting is stronger than his case for holding. The bull proved the operating improvement is real: revenue of $2.05B was up 33.7% year over year, sequential growth accelerated for four quarters, the incremental operating margin was about 32%, and SG&A fell from about 16% to 13% of revenue. The balance sheet is not a solvency issue, with net debt about 1.0-1.3x EBITDA and the preferred converted. The bear proved cash is the weak link: trailing FCF is about -$1.0B, June capex of $563M was about 110% of normalized EBITDA, and inventory is at 187 days versus 133. June operating cash flow was positive only because of about $334M from payables and accruals. The bull dropped his 51% incremental EBITDA margin because it included non-operating income. On cleaner numbers the stock trades at about 37x June-annualized and about 30x the bull's FY27 EBITDA of $2.2B. The deciding point: the bull's own four-scenario weights give about $316 against $319, below the 6-7% hurdle both accepted. Updating the miss case to his own $180-185 tripwire scenario lowers it to about $307-312. He also admitted his 4:1 skew was conditional, that he has no evidence of beating expectations, and that his upside case leans on June's +13.3% quarter. The technicals are a range, not a breakout: ADX is about 7, the daily trend indicator is down, the Sep 18-21 move failed, and the 10.9% day on October 1 has no verified catalyst and looks like a crowded optical-sector move. Daily ATR of 6.7% means a bad November print can gap through any exit. I'm not choosing Sell because the business is improving and neither side supports a short. I'm not choosing Hold because even the bull says not to carry a full position into November at $319. Data gaps: no vendor valuation data, peer multiples, guidance, backlog, consensus or verified catalyst; the November date is unconfirmed; the sell-side notes came secondhand from StockTwits.

Strategic Actions: 1) Trim to tracking size now: about 25-35% of a standard allocation, sized so a fall to $185 (-42%) costs under 1% of the portfolio (at most about 2% of the portfolio). If there's no position, don't start one at $319. 2) Don't add between $319 and $332, where resistance sits at $321.5, $327 and $332. A daily close above $332 alone is not a reason to add; it needs volume confirmation and on-balance volume above 312.3M. 3) Re-entry ladder: before November, add one tranche at $265-275, up to about 50% of standard; don't buy at $290-295. After a clean November print that passes all four tests, build toward a full standard allocation at $280-295; don't chase at $345 or higher. 4) The four tests: inventory growth below revenue growth with inventory days heading toward the 160s; gross margin of 38% or more; operating cash flow above 50% of EBITDA; free cash flow after capex improving quarter over quarter. 5) Exit the tracking position on any of: sequential revenue growth below 3% while inventory days rise; gross margin below 38%; payables unwinding while operating cash flow stays near zero; inventory days above 200; any equity raise. 6) Plan for gap risk by relying on position size rather than stop orders; treat the $255 weekly level as a trend marker, not a risk limit. 7) Before the report: confirm the earnings date, identify the $44M write-off, check the roughly $2B equity raise in the filings, and check FY27 capex guidance. Guidance at or below about $2.1B, together with passing tests, supports an upgrade to Overweight.

III. Trading Team Plan¶

Trader¶

Action: Sell

Reasoning: The plan's Underweight is a Sell: trim to a tracking position. The business is improving (revenue +33.7% y/y, about 32% incremental operating margin), but trailing FCF is about -$1.0B and inventory is at 187 days. The bull's own scenario weights give about $316 against a $319 price, below the 6-7% hurdle. Technicals show a range, not a trend: ADX is 7, the daily SuperTrend is DOWN with its stop at 332.01, and the 10.9% jump on 10/1 has no verified catalyst and sits under resistance at 321.5, 327 and 332. ATR of 6.7% means a November gap can pass through any stop, so size is the risk control.

Entry Price: 319.19

Stop Loss: not provided

Position Sizing: Trim to about 25-35% of a standard allocation, sized so a fall to $185 costs under 1% of the portfolio (at most about 2%). If there is no position, do not start one at $319. Re-entry: add one tranche at $265-275, up to about 50% of standard, before November. Build toward full size at $280-295 only after a clean November print passes all four tests.

FINAL TRANSACTION PROPOSAL: SELL

IV. Risk Management Team Decision¶

Aggressive Analyst¶

Aggressive Analyst: I'll open, since nobody else has spoken. I expect to be called the odd one out for defending a Sell, so let me say why this is the aggressive position. Aggression doesn't mean holding the biggest bag into a 10.9% spike. It means refusing to pay a full price for a stock whose own bull case already sits at roughly today's price, and keeping capital and conviction ready for the entry where the payoff is lopsided.

Start with the math. The bull scenario weights come out near $316 against a $319 price. That's a negative expected return before we even ask for the 6-7% hurdle. Chasing a stock where the upside is already in the price is not bold, it's paying retail for the optimism. Even the Bernstein $350 target, which is secondhand from StockTwits and unverified, is only about 10% above here. From the $265-275 zone in the plan, the same target is about 30%. Same stock and same thesis, with three times the reward for the same view. Waiting for that entry is the high-reward move.

The business is excellent, and I won't pretend otherwise. Revenue is up 33.7% year over year, operating margin went from 9.5% to 14.9% in four quarters, and operating income more than doubled. That's exactly why a tracking position makes sense instead of a full exit. But the cash flow is a different story. Trailing free cash flow is about negative $1.0 billion. Operating cash flow is about $80 million against roughly $805 million of net income. Capex was $563 million last quarter alone, four times a year ago. Inventory is $2.58 billion, up 80%, at about 187 days. Cash and investments fell about $430 million in one quarter. If capex stays near that pace, the roughly $2 billion cushion lasts only a few quarters, and the company already diluted about 30% in a year. A company with a stock at highs and a cash burn like this has an obvious way to fund itself, and it isn't kind to holders.

The technicals don't give anyone a trend to ride. ADX is 7. The 10 EMA, 50 SMA and 200 SMA are all within ten points of each other. Closes went 321.5, then 290.6, then 287.8, then 319.2 in about eight sessions. The daily SuperTrend is still down with its stop at 332, and the bounce stalls under three resistance levels at 321.5, 327 and 332. The jump has no verified catalyst. The news tool returned nothing, and the sentiment is one day of thin StockTwits chatter, including someone selling 80% at $319 and a post with unverified but pointed concerns about inventory and cash flow.

Now the objections I expect.

To the neutral analyst, who I expect to say the weekly and monthly SuperTrends are up, price is above every average, and that argues for holding full size: those are real, and that's why I keep a position rather than going to zero. But the weekly stop is 255 and the monthly is 229. Those are 20-40% below price, so they tell you the long-term trend is intact, not that $319 is a good place to add. With ADX at 7, the MA ordering is noise from tightly clustered averages. Early August hit $379 and by September 3 it was $264, a drop of about 30% in a month. A stock that does that doesn't reward full-size complacency.

To the conservative analyst, who will probably say exit completely or demand a hard stop: a stop is the wrong tool here. ATR is 21 points, about 6.7% a day. A tight stop gets hit by noise, and a November earnings gap goes straight through any stop anyway. The plan controls risk through size. Trimmed to 25-35% of standard, a fall to $185 costs under 1% of the portfolio, at most about 2%. And leaving the position open keeps us in the game if the breakout is real. Closing everything would mean either chasing back in above 332 or missing a stock with accelerating revenue and expanding margins. A tracking position gives participation without exposure that can hurt.

The honest cost of my view is that if COHR runs through 332 and back toward the $427 June high, we'll own less than we could have. I accept that. The plan rebuilds in tranches, first at $265-275 up to about half of standard before November, then toward full size at $280-295 only after a clean print passes the plan's four tests. That's staged risk-taking: we put real size to work where the odds are skewed in our favor, instead of putting full size to work at the top of a range, under resistance, on a one-day move nobody can explain.

Two caveats. Valuation data was withheld, and the 26x forward P/E is an unverified retail claim, so I'm not leaning on it. And the November report date needs confirming. But the case doesn't depend on either. The price already discounts the good news, the cash flow is the weak link, and the setup rewards being a patient buyer.

My recommendation stays the same: trim to a tracking position, don't start a new one at $319, and keep the dry powder for lower prices.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: Before I answer you two, here's what I think the last rounds settled. All three of us say don't open a position at $319, and all three say that if you own it, you sell some. The live disagreements are how much to keep, whether to buy anything before the November print, and whether to attach a hard exit. I'll take those in turn and give ground where you've earned it.

Neutral is right that "stock at highs" was sloppy. At $319 it's about 25% below the June 2 close. But it's also up roughly 44% from the July 29 low of $222.05, and that's the kind of rebound companies raise money into. I'll also concede that one more $2B raise at around a $60B market cap is only about 3% dilution, and net debt at 1.3x EBITDA is not distress. So I'm dropping dilution as my headline. The real issue is earnings quality. About $805M of trailing net income produced roughly $80M of operating cash. Conservative's payables point makes it worse: payables went from $1.34B to $1.91B in one quarter, so even the -$493M free cash flow quarter had help from suppliers. If that reverses, the burn is bigger.

On sizing, Conservative is right that "under 1% of the portfolio" means nothing without knowing the book, and we don't. So the rule is this. Decide what loss you can live with if the 48% drawdown from June to July repeats, and size backward. Neutral's point that percent-of-standard and loss budget are one constraint is also right, so take the lower. For many books the loss cap binds, and then Neutral's half size and my third are the same number. I'd also count correlated names against that cap, but I'd check it. The evidence that COHR trades with LITE, AAOI, CIEN and VIAV is retail chatter plus a Gundlach headline with no text, so measure the correlation in the actual book.

Neutral, your 70% breakeven is built from mismatched pairs. You set a 15% pullback against a run to the full June high of $427. Use the plan's own downside of $185 instead, a 42% fall that this stock has shown it can deliver, and the extra 20% of a position costs about 8 points against 7 earned. Breakeven drops to roughly 45%, which is a coin flip. And the base case in the technical report is a range between about 294 and 327, where the extra size earns nothing. Your supporting evidence is thin too. ADX at 7 means the trend signals say little in either direction, and RSI at 56 is neutral. OBV at 303.6M is still below the 312.3M of September 21, which is the confirmation you want before adding back. The weekly and monthly SuperTrends are up, but their stops sit roughly 20% and 28% below price. That says the long trend is intact, not that $319 is a good place to carry more.

You're also right that my three-times-the-reward math leaned on the unverified Bernstein target, so let me redo it with levels from the tool output. At $319, the daily SuperTrend flip at $332 is about 4% away and the weekly stop at $255 is about 20% away. At $270, those distances are about 23% up and 5% down. They're distances, not forecasts. With ATR at 6.7%, I'm not calling $255 a stop, just where the thesis gets re-examined. As for fill risk, $270 is about 2.3 ATRs below here, and the stock closed at $264.41 on September 3 and $321.52 on September 21. If the order doesn't fill, we keep a tracking position and lose only time.

Conservative, your gap point on the pre-print tranche is fair in form. I accept Neutral's fix: the tranche is capped by what a 20-25% gap costs the book, whichever is lower, and we're smallest going into the print. But "add after results confirm" has no price rule, and Neutral is right that it ends in chasing a gap. My plan names prices and accepts missing the run. You say a revisit of $270 probably means something went wrong. Maybe. That's why the first tranche is small and real size waits for the print.

On exits, Neutral wins this one. The stock closed at $287.81 on September 30, just under the 200-day at $288.23, and then jumped 10.9%. A rule that sells there is a whipsaw machine. That's why I argued for size over stops from the start. A weekly close below $255 as a review trigger is fine. On insiders, I won't lean on it. A CFO who sells monthly at every price tells us little.

I'll take one improvement from Neutral: don't dump the trim at the open after an 11.4M-share day. Sell part now and part into the $321-332 resistance zone. And if your plan is to cut toward half in steps, that is a Sell on whatever you hold, just a partial one.

The cost of my view hasn't changed. If COHR clears $332 and runs back toward $427, we'll own less than we could have. But the plan's own scenario weights come to about $316 against a $319 price, and valuation data was withheld, so we can't underwrite paying up. When you can't price something, you don't pay full price for it. Everything here stops at the October 1 close, and the November report date is unconfirmed. I'd rather pay for the missing information in forgone upside than in capital.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: We're now at three Sells, which is an odd place for the analyst who's supposed to be pushing risk. So I'll say where the risk-taking is, and I'll start by conceding what you've earned.

Conservative, you're right that selling a real piece now beats waiting for $327-332. The high today was $323.23, barely through the $321.52 level that failed on September 21, so selling the whole second tranche into resistance assumes a move that may not come. Sell a real piece now and put the rest on limit orders with a deadline. You're also right that a "review" at $255 with no pre-committed action gets decided in the moment. And the payables point is fair. If part of that $570M jump is capex accruals, cash capex understates the build rate, and someone should check the filings before anyone calls the burn peaked. I'm dropping the $316 versus $319 argument for good, and Neutral is right that missing valuation data stops us calling the stock expensive just as it stops us calling it cheap. The case rests on cash conversion, a range regime, an unexplained 10.9% spike, and an unconfirmed print date.

Now the disagreements. The first is the pre-print tranche, where I think you have the risk backwards. Your adverse-selection point is real, but look at what the tranche is. It's a resting order at a price the stock has actually traded, with the lower Bollinger band at $262 and the September 3 close at $264. It's capped by the same loss budget you want, and Neutral already showed that a 25% gap is about half the 48% drawdown that cap assumes. From $270, a repeat of the trough near $166 is about a 38% loss, not 48%, so the cap measured from $319 has headroom at that entry. I won't spend that headroom. I'd treat it as the gap cushion. I'll also concede one thing. If the print date is confirmed, cancel any unfilled buy orders a few sessions before it.

The deeper point is that the technical base case is a range of roughly $294 to $327. In a range with ADX at 7, the edge is selling the top and buying the bottom. Sell at $327 and rebuy at $270, and the same dollars buy about 21% more shares. Waiting for confirmation, whether that's a close above $332, ADX turning up, or the print, means buying higher every time. Confirmation has a price. "We can always buy it back" is true of liquidity, because 4 to 11 million shares a day is plenty. It isn't true of price. This stock just moved 10.9% in a session.

On the $255 ladder, I'm with Neutral. A position already cut to its loss budget has paid for its drawdown in advance. Liquidating it at a level the stock touched near $264 on September 3 sells the low of the range. A weekly close below $255.29 halves what's left and a weekly close below $228.66 exits. That's pre-committed action, but it doesn't sell the bottom of a range the position was sized to survive.

On rebuilding, Neutral's fix improves my plan. I wrote $280-295 after a clean print, and that was a preference, not a rule. If capex guidance, inventory days and operating cash flow all improve, put in the first piece the next session even if it gaps above $295, up to the cap. This isn't chasing. Paying up after the print buys resolved uncertainty, while paying up today buys an unexplained spike under three resistance levels. Then add the rest after the post-print level holds for a week or on a pullback.

On sizing, the lower of the loss cap and half of standard is the right rule. Tolerable loss divided by 0.48 is the unmanaged ceiling, and correlated optics names count together until someone measures otherwise. Neutral is also right that a third versus a half isn't worth another round of debate if the cap binds.

The cost of my view is the same as before. If COHR clears $332 and runs back toward $427, we own less than we could have. I'd take that over holding full size under resistance on an unexplained one-day move, and I'd take it over giving up the discipline to buy at $270 or after a clean print. Everything here stops at the October 1 close.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: We're at three Sells, so I'll use my turn to say what I've lost, what I'm keeping, and where the bold part of this plan actually is.

Conservative, you're right about headroom, and Neutral's agreement settles it. The 48% stress already includes the slide from $319 to $270. If you hold a cap-sized position and the stock gets there, roughly a third of the loss budget is spent, and new money at $270 draws on the same budget. My claim that the drop from $270 to $166 is only 38% was true for the new shares and irrelevant to the book. Headroom exists only if you started below the cap. The same goes for the sell-$327, rebuy-$270 math. It gives 21% more shares only if both orders fill in that order. Today's high was $323.23, so the case where $270 fills and $327 doesn't is a broken range, and there you own more going into the print, not fewer. I'll stop selling the bid as technical support too. $270 is below the 200-day, the 50-day and the middle band, and the report says it has no evidence of bounces at these levels. If it fills, the range has probably already failed, and nobody should count on a bounce.

I'll also take the point that the first sale should be judged against the open on the 2^nd, not against $319. Our data stops at the October 1 close, and an unexplained 10.9% day can give back a chunk or extend. If you're above the cap, sell the real piece against the tape. If you're at or below it, there's nothing to sell.

Neutral, you're right that missed upside is a real cost, and it's the whole reason I want a pre-committed rebuy rule. Conservative keeps calling it "a small piece bought higher," and that only holds if the gap is modest. If the print is clean and the stock gaps 20%, we're underexposed to a move we said we believed in. Your refinement on the cash flow test is also better than Conservative's. A balance-sheet payables jump of $570M, even if part of it is capex accruals, never touched operating cash flow, so stripping it all from a $69.5M quarter would fail every print. The right test is the change-in-payables line on the cash flow statement, plus a check of whether unpaid capex is understating the real build rate. Judge the trend in inventory days and capex guidance alongside it.

Where I still disagree is narrow, and it matters less than the label fight suggests. Conservative, your point that a 15% discount doesn't pay for a 20-25% gap is only partly right. The discount doesn't compensate for gap risk, but it doesn't add to it either. A 22% down-gap hurts the same percentage at any entry, and the lower entry just starts from a better place. So the optional bid in the $262-275 zone is defensible if you hold less than the cap, if it's small, and if it's cancelled by the end of October or when a date is confirmed. If you're at the cap, it doesn't exist. I'm content to leave that as an optional, low-conviction tranche, and I'd say that disagreement doesn't change the direction.

Here's where the risk-taking is. The cautious versions of this plan treat the print as a reason to sit out. My version treats it as the price of admission. Before the print we're taking uncertainty nobody pays us for: an unexplained spike, an unconfirmed date, trailing free cash flow near negative $1.0B, and ADX at 7. After the print, if capex guidance flattens, inventory days fall and operating cash flow improves, the uncertainty is resolved and I'll pay up for it. That means putting the first piece in the next session even if it gaps above $295, up to the cap, and adding the rest once the post-print level holds for a week. That requires changing the trader's plan, because the $280-295 band shouldn't be a price ceiling on the rebuild. If the four tests pass, the band is irrelevant. We're paying for information, and I'd rather pay in price after the print than in capital before it.

The rule I'd hand anyone is this. Hold no more than the lower of half of standard or tolerable loss divided by 0.48, counting correlated optics names together until someone measures them. If you're above that, sell the excess in two pieces: a real one at the open against the tape, and the rest on limit orders in the $321-332 zone that expire by the end of October. If you're flat, don't buy at $319. A weekly close below $255.29 halves what's left, and a weekly close below $228.66 exits. That ladder is a backstop, since a weekly close is checked once a week and ATR is 21 points, so the cap does the real work. After the print, rebuild in the order above.

The cost of my view is the same as before. If COHR clears $332 and runs back toward $427, we'll own about half of what we could have. I'll take that over holding full size under three resistance levels on a move nobody can explain.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: I'll keep this short, since most of it is settled, but I'll say where I've moved and where I haven't.

Conservative, you're right on the deadline. A cap that depends on limit orders filling in a zone the stock has barely traded isn't a cap. Today's high was 323.23, and if the stock slides back into the 294-298 cluster, those orders sit there while you carry the excess into a print nobody has dated. Anything unfilled at the deadline sells at market. The cost is real, roughly 9% worse on that slice, but it's small next to what the cap protects against. I'd tie the deadline to the earlier of the end of October or a few sessions before a confirmed date. The missing date is a reason to move it earlier, not later.

You've also worn me down on the pre-print bid. A fill near 270 means the stock has gone through the 200-day, the 50-day and the middle band, so the range has probably failed. It draws on the same loss budget, and without valuation data "cheaper than 319" isn't an edge. I argued it was defensible, but I can't name what it buys us that the post-print rebuild doesn't buy with less uncertainty. So the pre-November tranche comes out of the plan, and that's a real change to what the trader wrote.

Neutral, I agree that half of standard shouldn't be a permanent ceiling. It's a ceiling because we're carrying an undated print, an unexplained spike and a cash-flow question. If the print resolves those, the loss budget alone should decide how far toward full size we go. Otherwise we'd trade one error for the opposite one.

I'd push back on one thing in your open-the-chart caveat. You said a verifiable catalyst would weaken the unexplained-spike leg. That's true, but the kind of catalyst matters. The three items in the sentiment report are the Bernstein target, the Citi optical-switching note and the Morgan Stanley FCC note, and all of them are secondhand analyst or regulatory chatter. None of them touches the actual weak point, which is trailing free cash flow near negative $1.0B and quarterly capex four times last year's. A new price target doesn't make the burn smaller. Only company-sourced information does, like guidance, a filing or a customer commitment. So I'd reconsider the cap for that, not for another broker note.

Since the real risk-taking now sits in the rebuild, I'd make the rebuild rule as mechanical as the sell rule. If capex guidance shows the $563M quarterly pace peaking, inventory days fall from about 187, and operating cash flow on the cash flow statement beats the $69.5M quarter without payables doing the work, then the first piece goes in the next session, spread through the day, even if it gaps above the old $280-295 band. The unpaid-capex disclosure gets checked too, so we judge capex on an accrual basis. If two of the three pass, the first piece is smaller. If they fail, we stay at the cap or go lower. The rest goes in once the post-print level holds for a week, up to whatever the loss budget allows. Nobody has to decide anything in the moment, because paying up after a print buys resolved uncertainty and paying up today doesn't.

Neutral's warning on that is fair. A good print isn't a good price, and the plan shouldn't promise the rebuild will be cheap. It buys certainty, not a discount, and I'm fine saying so.

So the rule is the same one we've all converged on, minus the pre-print bid. Hold no more than the lower of half of standard or tolerable loss divided by 0.48, counting the other optics names together until someone measures them. Sell the excess in two pieces, a real one against the tape at the open, because our data stops at the October 1 close and today is the 2^nd, and the rest on limits in the 321-332 zone with a market sale at the deadline. If you're flat, don't buy at 319. A weekly close below 255.29 halves what's left, one below 228.66 exits, and both are backstops while the cap does the real work. Then rebuild by the tests above.

The cost is the same as before. If COHR clears 332 and runs toward 427, we'll own about half of what we could have. I'll take that over holding full size under three resistance levels on a move nobody can explain, with the cash burn unresolved and the print undated.

FINAL TRANSACTION PROPOSAL: SELL

Conservative Analyst¶

Conservative Analyst: I'm closer to you than the labels suggest, which is worth noticing. You call a trim-to-tracking Sell the aggressive stance, and I agree with the direction. But the plan still carries more risk than you're admitting, and several of your arguments for keeping it that way don't hold up.

Start with sizing. You say a fall to $185 costs under 1% of the portfolio, at most 2%. We don't know the portfolio, so that's only true for a particular allocation. Work it backwards: a 42% fall costing 1% means the tracking position is already about 2.4% of the book. At 25-35% of standard, that implies a standard position of roughly seven to ten percent in one stock, and for the 2% figure it's well into the teens. Also, $185 isn't a tail scenario. The stock went from $426.89 on June 2 to $222.05 on July 29, a 48% drawdown in under two months, and then fell from $379 to $264 in the following month. I'd state the rule as a loss budget. If a repeat of that 48% drawdown shouldn't cost more than about 1% of the book, the position can't be more than about 2% of the portfolio. Whoever applies this can plug in their own tolerance.

On stops, you say ATR is 21 points, so stops get hit by noise. That's an argument against a tight stop, and nobody needs one. The 200-day at $288 is about one and a half ATRs below the price, and the weekly SuperTrend stop at $255 is about three ATRs below. Those are structural levels, not noise levels. The stop-loss field in the plan is empty, and a tracking position with no exit rule is just a position we've agreed to stop thinking about. I'd want a rule: a daily close below $288 cuts it again, and a weekly close below $255 closes it.

Your gap argument also cuts against your own re-entry plan. You say a November gap goes through any stop, so size is the control. Agreed. But then the plan buys a tranche at $265-275, up to half of standard, before November. That adds exposure ahead of the one event you say can't be hedged, and the report date still isn't confirmed. If gap risk is the concern, we should be smallest going into the print and add after it, even at a worse price.

The $265-275 entry has its own problems. The "three times the reward" math rests on the $350 Bernstein target, which you called secondhand and unverified a paragraph earlier. And if the stock does revisit $270, it will probably be because something went wrong, like a cash-flow scare or a bad day for the whole sector. With a 6.7% daily ATR, $270 isn't a floor. You also didn't mention insiders. The CTO sold about $3.6M at $271-277 on September 1, directors sold in the high $260s and $270s, and there's been no open-market buying since late 2024. The selling is small and consistent with diversification, so I won't oversell it. Still, the people who know the business best weren't treating $270 as a bargain.

On cash flow, I think you understate it slightly. Payables jumped from $1.34B to $1.91B in one quarter, which temporarily supports cash. So the -$493M free cash flow quarter was helped by supplier terms, and if that reverses, the burn looks worse. Add 187 days of inventory against 133 a year ago, $1.56B of work in process, and goodwill and intangibles at about 40% of assets. To be fair, net debt is only about 1.3x EBITDA, so this isn't a distress story. The risk is dilution from a company that already diluted about 30% in a year, and that risk is real even if the business is excellent.

I'll also preempt the neutral analyst. "Price above all three averages" describes one day. On September 30 the stock closed a hair below the 200-day, and with the averages within ten points of each other and ADX at 7, their ordering tells us nothing. The last time COHR was at $321 on September 21, it was at $290 three sessions later. The daily SuperTrend flip is only about 4% away, less than a typical day's move, and the technical report itself says trend signals are unreliable at this ADX. Paying up for a confirmation the regime says is unreliable isn't prudence.

The cost of my version is that if COHR runs to $332 and then $427, we own very little. That's an opportunity cost, not a capital loss, and a stock trading 4-11 million shares a day can be bought back whenever we choose.

So I support the Sell, with tighter terms. Size the tracking position by loss budget, around 2% of the book or less. Set explicit exit levels at $288 and $255. Make no adds before the print, and re-enter after results confirm the cash-flow story.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: Before I get into it: the three of us now agree on most of the substance. Nobody starts at $319, anyone holding trims, size comes from a loss budget, and the daily $288 trigger is dead. I'll take that last one first. Neutral is right that it would have sold the day before a 10.9% rally. On a position already cut to a third, a whipsaw costs a few points of a standard position, but I won't defend a rule that fires at the worst moment. I'll also drop the $316 vs $319 expected-value argument. Neutral is right that it sits inside the error of a scenario exercise built without valuation data. My case never needed it.

The case is the cash flow, the volatility regime, the event risk, and not knowing why the stock jumped. Trailing free cash flow is about negative $1.0B. The June quarter alone was negative $493M against $1.99B of cash and investments, which is about four quarters at that pace. Neutral's debt math is fair, and I agree this isn't distress. But the financing decision belongs to the company, and companies choose their moment. On my own rough arithmetic, 196-202M shares at $319 is a market cap of $62-65B. That's roughly 40x trailing normalized EBITDA, and low 30s even if the best quarter holds. Those are my numbers, not the vendor's, because valuation data was withheld. That's a price that needs the capex to turn into cash, and nothing in the data shows it has yet. Aggressive, on payables: the fundamentals report says the jump from $1.34B to $1.91B likely reflects capex and inventory purchases. If part of it is capex payables, reported cash capex may understate the real build rate. That's worth checking in the filings before anyone calls the cash flow bottomed.

Aggressive, here's where I still part ways with you. Your plan buys up to half of standard at $265-275 before November. You accepted a cap, but the plan's own text still has that tranche going in ahead of a print whose date nobody has confirmed. A resting limit order is also adverse selection. It fills when the stock is falling, and if the weakness arrives as a gap, it fills at a worse price. Neutral thinks a 20-25% earnings gap is plausible. From $270 that lands at $202-216, below the July low of $222. You say that if the order doesn't fill we only lose time. The same is true of waiting until after the print, where we lose price and not capital. This stock trades 4-11 million shares a day, so we can always buy it back.

Your staged selling has the same flaw. Today's high was $323.23, barely through the $321.52 level that failed on September 21, when the stock was at $290 three sessions later. Selling into $327-332 assumes it gets there. Sell a real piece now, while volume is double normal and liquidity is as good as it gets, and put the rest on limit orders with a deadline. Otherwise you hold the larger size through the weak side. On exits, calling $255 a re-examination point isn't enough. A review with no pre-committed action gets decided in the moment, usually after a gap.

Neutral, your sizing logic is right, and I'm happy to take the lower of percent-of-standard and the loss budget. Your Hold label is my problem. A reader with a full-size position will take Hold as "do nothing," and your own plan says to sell the excess. The label is part of the risk control, so it should say Sell.

I also think you apply your own consistency test unevenly. You told me I can't distrust SuperTrend flips at ADX 7 and then use SuperTrend levels as exits. But you add back to two-thirds on a close above $332.01, which is a daily SuperTrend flip, and you do it before the print, which breaks your own gap budget. The tool says those flips are unreliable in this regime. My answer to your charge is that a price level used to define a loss budget is a measuring stick, not a forecast, which is what Aggressive said about distances. A signal used to justify adding risk is a bet that the signal works, and the technical report says it doesn't at ADX 7. So no adds on a $332 close alone. Wait for the print, or at least for ADX to turn up from the single digits.

On breakeven, Aggressive's correction is right. Against the plan's $185 downside, the odds are a coin flip, not 70%. And $185 is the mild case. A repeat of the June-to-July drawdown of 48% from here is about $166. The technical base case is a range, where the extra size earns nothing. I'd also keep your correlation point and strengthen it. Aggressive wants to measure correlation with LITE, AAOI, CIEN and VIAV in the actual book. That's sensible, but with news, macro and valuation data all missing, the default until measured should be that they move together.

Here is the rule anyone can apply to their own book. Maximum position equals your tolerable loss divided by 0.48. A 1% loss budget means about 2% of the book, and a 2% budget means about 4%, with correlated optics names counted together. Take that or half of standard, whichever is smaller. Trim part now and the rest into $327-332 with a deadline. Don't add before the print. If you're flat, don't buy at $319. After the print, if capex guidance, inventory days and operating cash flow all improve, rebuild in steps. If a weekly close below $255.29 comes first, the uptrend you were tracking is gone, so go to zero or a token holding.

The cost of my view is the same as before. If COHR runs through $332 toward $427, we own less than we could have. That's missed upside, not lost capital.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: We've converged on most of it, so I'll spend my time where I think the other two are still carrying risk they haven't priced. First, what I'll give up. The $288 daily trigger is dead, and so is the $316 versus $319 argument. I'll take the ladder in principle: a weekly close below $255.29 is a pre-committed cut, not a review. But a weekly close is checked once a week and ATR is 21 points a day, so the stock can be well through $255 before the rule fires. Nobody should use the ladder to justify a position bigger than the 0.48 cap allows. I'll also accept a first rebuy piece the session after a clean print, with one condition: judge operating cash flow excluding the payables swing, since we all agreed that line may be flattering the cash.

Aggressive, your headroom argument is a mistake. You said that from $270 a fall to $166 is only 38%, so the cap measured from $319 leaves room. But the 48% already includes the 15% on the way down to $270. If you hold a cap-sized position and the stock reaches $270, you've spent about a third of your loss budget. The rest of the drop to $166 spends the remainder. Buy more at $270 and you add roughly 38% of the new money in loss on a budget that's already committed. Headroom exists only if you started below the cap, and then it's the half-of-standard limit that matters. Buying lower doesn't earn you a new cushion.

I also don't think $270 is the bottom of the range. The technical report's base case is about $294 to $327. $270 sits below the 200-day, the 50-day, the middle band, and the report's own bearish trigger. A fill there means the range has already failed. The report also says it has no tool evidence of bounces at the levels we keep calling support. The $264 close on September 3 was one day in a slide from $379, and the lower Bollinger band moves every day. I'd call that order a bid under a falling stock.

You said paying up after the print buys resolved uncertainty. I agree, and the same logic says buying before it buys unresolved uncertainty. The question is whether the discount pays for that. The discount is about 15%, and Neutral's own estimate of a plausible earnings gap is 20 to 25% in either direction. You'd be paid 15% to take a bet with a larger swing on each side. It would also settle capex guidance, inventory days and operating cash flow, which is what the whole thesis turns on. The cost of waiting is bounded: a small piece bought higher. The cost of being early is the part of the loss that doesn't come back.

Your sell at $327, rebuy at $270 math gives 21% more shares, but only if both orders fill in that order. Today's high was $323.23, so $327 hasn't traded. The case where $270 fills and $327 doesn't is a stock that broke down, and there you own more shares into the print, not fewer. The 21% exists only in the version where the range holds, and a 48% drawdown in under two months is a reason not to assume that. I do accept your concession to cancel unfilled buys before the print. But the date is unconfirmed, and the report says fiscal Q1 normally lands in early to mid November. So the rule should be to cancel by the end of October, or earlier if a date is confirmed.

Neutral, same issue with your pre-print add after a pullback, small and inside the cap. Count the loss already taken on the way down, and it only fits if there's unused budget. Even then, I'd ask why. It's a rule to buy weakness in a name with about negative $1.0B of trailing free cash flow, a month before the quarter that shows whether that turns. I'd rather pay up afterward than guess beforehand.

You're right that I shouldn't call the stock expensive on a number the vendor withheld. My rough math is low 30s EV to annualized best-quarter EBITDA, and I'm not selling on that. But a multiple like that leaves no cushion if the $563M quarterly capex doesn't turn into cash, which is another reason to avoid adding.

One practical point. Our numbers stop at the October 1 close and today is the 2^nd, after a 10.9% day nobody can explain. Execute the first piece against what the tape shows at the open, not against $319.

So the rule I'd hand to anyone is this. Hold no more than the lower of half of standard or your tolerable loss divided by 0.48, counting correlated optics names together. Sell the excess in two pieces: a real one now, and the rest on limit orders in the $321-332 zone that expire well before the print. Make no adds before the print. A weekly close below $255.29 halves what's left, and one below $228.66 exits. After the print, put in a first piece the next session if capex guidance, inventory days and operating cash flow ex-payables all improve, and the rest after the stock holds for a week.

The cost is the same as before. If COHR runs to $427, we own less than we could have. That's missed upside, not lost capital.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: We're close enough now that I'll only argue about the things that could still cost someone money.

Aggressive, first, I'm glad you dropped the $280-295 ceiling on the rebuild. Paying up after the print is the same logic I've been using, so we agree there. I'd add one execution point. A stock with a 6.7% ATR that gaps on earnings is at its least orderly in the first minutes of the session. Put the first piece in the next session if the tests pass, but spread it through the day instead of lifting the open.

Neutral, you're right about my ex-payables test. Capex accruals never ran through operating cash flow. They made cash capex look smaller. So there are two checks. One is the change in payables line in the operating section of the cash flow statement, judged as a trend. The other is the unpaid-capex disclosure, so capex gets judged on an accrual basis. Stripping the whole $570M from a $69.5M quarter would fail every print, as you said.

You're also right that missed upside is a real cost. But the held position already participates in a gap up, because the cap is the lower of half of standard or the loss limit, not zero. What we give up is the difference between that and full size, and the first-piece rule covers part of it. I'd still treat half as a ceiling and not a target while nobody has measured the correlation with the other optics names. Tax lots are a reason to choose which shares to sell, not a reason to carry more risk than the cap allows.

Now the part I think nobody has fixed yet. We say the limit sells in the $321-332 zone expire by the end of October. What happens to the excess if they don't fill? Today's high was $323.23, so that zone has barely traded. If the stock slides back into the 294-298 cluster, the orders sit unfilled and you go into the print above your cap, which is the outcome the cap was meant to prevent. This is the same flaw as a review with no pre-committed action. The rule should say that whatever excess is left at the deadline, or earlier if the date is confirmed, sells at the market. The cap is a risk limit, not a price view.

On the optional pre-print bid at $262-275, Aggressive, you're right that a 22% down-gap costs the same percentage at any entry. But that's the problem, not a defense. The bid adds new money that takes the full gap loss, and it only fills when the stock is already weak. Both of you have also conceded the rest of the case against it. A fill at $270 sits below the 200-day, the 50-day and the middle band, so the range has probably failed. And without valuation data, "cheaper than $319" isn't an edge, because we can't say what the stock is worth at either price. Unused budget is a reason the bid is allowed, not a reason to place it. After the print, the same budget buys resolved uncertainty. Neutral, I'd rather write it as "no adds before the print." An optional exception for people below the cap tends to get used on the worst day.

One last note on the 0.48 divisor. It comes from one episode, June 2 to July 29, a drop from $426.89 to $222.05. It is a stress example and not a ceiling, and a gap can go through any ladder. That's why the cap does the real work and the $255.29 and $228.66 weekly closes are only backstops.

So my rule is unchanged. Hold no more than the lower of half of standard or tolerable loss divided by 0.48, counting the other optics names together until someone measures them. Sell the excess in two pieces: a real one against the tape at the open, and the rest on limits in the $321-332 zone, with a market sale at the deadline for anything unfilled. No adds before the print, and nothing at $319 if you're flat. A weekly close below $255.29 halves what's left, and one below $228.66 exits. After the print, if capex guidance, inventory days and operating cash flow on the cash flow statement all improve, put in the first piece the next session and the rest once the level holds for a week.

If COHR runs to $427, we'll own less than we could have. I'd rather explain that than a position bigger than our loss budget going into a print nobody has dated.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: We're close enough now that I'll skip the settled items and press the few spots where I think the plan still carries risk. Neutral, thank you for the deadline fix. Aggressive, thank you for dropping the pre-print bid. The pre-November tranche is gone, and that's a real improvement on the trader's plan.

Aggressive, I want to challenge your rebuild rule, because that's where most of the remaining risk sits. The trader's plan said a clean print has to pass all four tests. Your version lets two of three tests justify a smaller first piece. On a stock with trailing free cash flow near negative $1.0B, partial credit is how a position drifts back to full size. If two of three pass, stay at the cap and wait.

The operating cash flow test is also too soft. Beating a $69.5M quarter is a very low bar, because trailing operating cash flow is only about $80M against roughly $805M of net income. Capex "peaking" at $563M a quarter still leaves a burn of several hundred million a quarter against $1.99B of cash and investments. I'd want operating cash flow covering a meaningful share of capex, and cash and investments no longer falling, not just a better number than last quarter.

Your own point about a good print being a good time to raise money cuts against the next-session first piece. The March quarter already looks like a roughly $2B raise. If the company funds the build right after a strong report, the first piece buys a stock that is about to be diluted. So I'd keep the next-session piece small, a third of what the cap allows, and only if the print and call say nothing about new financing, a shelf or an at-the-market program.

Neutral, you said the loss budget alone should set how far to go toward full size after the print. I agree, but notice what that means. The 0.48 stress doesn't shrink because the print was good, so for most books the loss cap already binds below full size. "Toward full size" will rarely be reachable, and the plan shouldn't suggest it is. I'd also keep half of standard as the ceiling until a second quarter confirms the cash story. One quarter can be flattered by payables timing, and the balance sheet shows a $570M jump in one quarter.

On the deadline, I'd shorten it. The cap says the excess shouldn't be held, and every week it sits on unfilled limits is a week above the cap. End of October is roughly two weeks before a typical early-to-mid-November report, and that stretch is where a slide back into the 294-298 cluster would happen. I'd make the limits good for about two weeks, mid-October at the latest, or a few sessions before a confirmed date, then sell the rest at market. Neutral, you priced the cost at about 9% on that slice and said you'd pay it, so a shorter window only brings that decision forward. And if the stock closes back below the 10 EMA and middle band, around 294-298, before the deadline, I'd sell the remaining excess then. That isn't the $288 trigger I dropped. That trigger cut a position already at its cap and whipsawed. This one finishes getting down to the cap, and the only cost is selling the excess a bit lower.

Neutral, I agree this is a sizing call and not a verdict on the business. Revenue is up 34% and operating margin is 14.9%. But the Sell label matters because it controls behavior. A holder at full size who reads Hold does nothing, and that's the outcome the cap exists to prevent.

Aggressive, you're right that a broker note doesn't change the cash-flow question, and I'd go one step further. A price move at the open isn't a catalyst either. Only company-sourced information should reopen the cap. Also, the 10.9% jump came with chatter about LITE, AAOI, CIEN and VIAV, so if this was a sector move it can reverse as a sector move. That's one more reason to sell the real piece against the open and not wait for a retest of 319.

So here's the rule I'd hand over. Hold no more than the lower of half of standard or tolerable loss divided by 0.48, counting the other optics names together. If you're above it, sell the excess in two pieces: a real one against the open, and the rest on limits in the 321-332 zone that expire by mid-October or a few sessions before a confirmed date. Sell whatever is unfilled at market. Add nothing before the print, and don't buy at 319 if you're flat. A weekly close below 255.29 halves what's left, and one below 228.66 exits, but those are backstops. After the print, a first piece goes in only if all the tests pass, including cash and investments no longer falling and no new financing. Size it small, spread it through the day, and add the rest after the level holds for a week. Half of standard stays the ceiling until a second quarter confirms the cash story.

If COHR runs to 427, we'll own less than we could have. That's missed upside, not lost capital, and I'd rather explain it than a position above our loss budget going into a print nobody has dated.

FINAL TRANSACTION PROPOSAL: SELL

Neutral Analyst¶

Neutral Analyst: You two agree more than the labels suggest. You both want a quarter to a third of standard size, both treat $319 as a bad place to add, and both want to rebuild after the print. That agreement is too comfortable, because each of you has a weak spot the other didn't press.

Aggressive first. You said a company with a cash burn and the stock at highs has an obvious way to fund itself. The stock isn't at highs. At $319 it's about 25% below the June 2 close of $426.89 and well under the $379 rebound in early August. Funding also isn't as forced as you make it sound. Net debt is about 1.3x trailing EBITDA, and adding $2B of debt would put it near 2.6x trailing, closer to 2x on the current quarterly run rate. Much of the 30% share count increase was the preferred converting, plus the roughly $2B raise the fundamentals report infers, which still needs checking in the filings. A further $2B at roughly a $60B market cap, my own estimate, would be about 3% dilution. That's worth watching, but it doesn't justify being at a third of size.

Your three-times-the-reward math is also conditional. The stock has to fall about 15% first, the order has to fill, and the target is the unverified Bernstein number. The plan's $316 expected value comes from scenario weights built without any valuation data. Whether the true figure is minus 1% or plus 6% is inside the error of that exercise. That argues against adding at $319, not for cutting to a third.

Here's the cost of the smaller size, with round numbers for illustration. Say the pullback is 15% and the breakout is to the June high, about 34%. Half size instead of 30% costs about 3 points of a standard position in the pullback and earns about 7 in the breakout. You'd need roughly 70% confidence in the pullback to prefer the smaller size. Nothing in this data gets anyone there. ADX is 7, RSI is 56, OBV and MFI have been improving, the weekly and monthly SuperTrends are up, and revenue growth keeps accelerating.

Conservative, your exit rules are built from the indicators you just dismissed. You say MA ordering and SuperTrend flips are unreliable at ADX 7, then make the 200-day at $288.23 and the weekly SuperTrend stop at $255.29 the exit triggers. Either those levels carry information or they don't. The $288 rule is also a hair trigger. The stock closed at $287.81 the day before this 10.9% rally and at $290.61 on September 24. A rule that fires the day before the rally, on a position already cut, just whipsaws you. And then what, buy back at $319? I'd keep the weekly $255 level as a review point and drop the daily one.

Your insider read is thinner than you made it. The CTO and directors did sell at $268-277. But the CFO has sold every month since February at prices from $217 to $373, including $324 in August, and a director sold at $306 in September. People who sell at every price tell us little about whether $270 is cheap. The fundamentals report's "neutral to mildly negative" is the right weight.

Your no-adds-before-the-print point is your best one, but it should be a budget, not an absolute. A 10.9% move on no company news makes a 20-25% earnings gap plausible, which is my judgment. So size total pre-print exposure so that gap costs a number the book can absorb. Inside that cap, a small tranche near $262-275 is defensible. That zone is the lower Bollinger band and the September 3 close of $264.41, so it's a tested area, not a guess. And "re-enter after results confirm" has no price rule. If the print is good and it gaps up 15%, you're chasing, which is the thing you've been criticizing.

On sizing, you did the same math from opposite ends. The percent-of-standard figure and the loss budget are one constraint, so take whichever is lower. If standard is 4% of the book, half is 2%, which fits your cap. If standard is 10%, half is 5%, the cap wins, and you sit below half.

One thing neither of you raised is that this wasn't only a COHR move. The chatter lumps in LITE, AAOI, CIEN and VIAV, and there's a Gundlach headline about fragile market leadership. The real risk is a single AI-optics factor. If the book already holds other names in that group, count the loss budget across all of them. That argues for smaller COHR size more than any COHR indicator does. News, macro and valuation data were all missing this week, so the rules should be simple enough to survive that.

So my version is this. If you hold it, trim toward about half of standard or the loss-budget cap, whichever is smaller, and do it in steps into the $321-332 resistance zone instead of all at once. If you're flat, don't start at $319. Place a small limit order in the $262-275 zone, sized under the gap budget. If it closes above $332.01 with OBV making a new high above 312.3M, add back up to about two-thirds. A weekly close below $255 triggers a review and a cut toward a third. Rebuild toward full size only after the print shows capex guidance, inventory days and operating cash flow moving the right way.

That keeps most of the protection you both want without paying much in missed upside if you're wrong about the pullback. I'd call it a Hold with a trim bias, not a Sell.

FINAL TRANSACTION PROPOSAL: HOLD Neutral Analyst: I'll skip what's settled: nobody starts at $319, the $288 trigger is dead, and size comes from a loss budget. Four things are still open: the label, the pre-print tranche, what happens at $255, and how to rebuild.

On the label, Conservative is right and I'm changing mine. Last round I said Hold with a trim bias, but my own target is the lower of half of standard or the loss cap, and that's underweight. The trader's plan treats Underweight as a Sell, and someone holding full size would read Hold as "do nothing." So I'll call it Sell. I'm keeping the size of the sell, though. It's a sale down to a cap, not down to a token.

Aggressive, I appreciate you dropping dilution and the stops, but you closed by leaning on $316 against $319 again. Conservative and I both said that sits inside the error of a scenario exercise with no valuation data. "When you can't price something, you don't pay full price" also cuts both ways. Missing valuation data stops us calling the stock cheap, and it equally stops us calling it expensive. The sell case doesn't need it. It rests on weak cash conversion, a range regime, an unconfirmed event date and an unexplained spike.

I accept your breakeven correction. Against $185 it's about a coin flip. But if it's a coin flip, a third versus a half isn't worth this much argument. Both the 42% fall and the run to $427 are tails, and the base case is a range where neither size earns much. Size by the cap and move on.

Conservative, I'll concede a few things. Your consistency charge on my $332 add-back is fair. A SuperTrend flip at ADX 7 isn't a reason to add risk before the print, so I'm dropping it. I also accept selling a real piece now and putting the rest on limit orders with a deadline. I wouldn't lean on the liquidity argument, since a stock that trades 4 to 11 million shares a day is liquid on any session. The better reason is that it closed near the high of an unexplained 10.9% day, under three resistance levels, and the last time it was at $321 it was at $290 three sessions later.

Here's where I still disagree. First, the pre-print tranche. Your gap argument is strong in spirit, but the rule you proposed already covers it. A 25% gap is about half of the 48% drawdown you size against, so the 0.48 cap is stricter than any gap budget. The tranche question is really whether to use headroom under that cap. I'd use it only after a pullback and only in small size, because that's when the price paid is better.

Second, going to zero at a weekly close below $255. You rejected the $288 trigger for whipsawing. Now you want to liquidate a position already cut to its loss budget at a level the stock traded near on September 3 ($264). I agree a review with no pre-committed action gets decided in the moment, so make it a ladder. A weekly close below $255.29 cuts what's left by half. A weekly close below $228.66, the monthly stop and close to the July low of $222, takes it to zero or a token. That treats the levels as measuring sticks, as you described.

Third, "we lose price, not capital" if we wait. Missed upside isn't free. A rebuild with no price rule can end up chasing a gap. So I'd put in a first piece the session after a clean print, even if it gaps, up to the cap. The rest would go in after the stock holds the post-print level for a week or pulls back.

On valuation, I'll take your rough numbers. But a trailing multiple around 40x is distorted by a year of fast margin expansion, and it's low 30s on the best quarter annualized. Whether that's rich depends on growth the data can't tell us. It's a reason not to add, not a reason to sell.

Your 0.48 divisor is the unmanaged worst case, and I'd keep it as the cap. The 255/229 ladder should improve on it, but gaps limit how much, so don't count on it. Count correlated optics names together by default and measure them if you can.

So the moderate Sell looks like this. If you're above the lower of half of standard or your loss cap, sell down to it, part now and part into $327 to $332 with a deadline well before the print, which still needs confirming. If you're at or below it, don't sell more and don't add at $319. Any pre-print add is small, only after a pullback, and inside the cap. A weekly close below $255.29 halves the rest, and a weekly close below $228.66 exits. After the print, rebuild only if capex guidance, inventory days and operating cash flow improve. If COHR runs to $427 we'll own about half of what we could have, and if it repeats the 48% drawdown we'll have lost about half as much.

FINAL TRANSACTION PROPOSAL: SELL Neutral Analyst: Most of this has converged, so I'll go straight to what's still open. The data also stops at the October 1 close and today is the 2^nd, so the first sale should be judged against the tape at the open, not against $319. Conservative is right about that. Also, an unexplained 10.9% day could easily give back part of itself before the sale gets done, so don't anchor on yesterday's close.

Aggressive, Conservative is right about headroom, and you should concede it. The 48% stress already includes the 15% slide to $270. If you hold a cap-sized position and the stock gets there, a third of the loss budget is gone, and a new tranche at $270 draws on the same budget. Headroom only exists if you started below the cap. Your sell-$327, rebuy-$270 math is also conditional on both orders filling in that order. Today's high was $323.23, and the case where $270 fills and $327 doesn't is a broken range, where you own more going into the print, not fewer. A range edge is real at ADX 7, but with a 6.7% ATR it's a noisy edge. It isn't a reason to pre-position for a print whose date nobody has confirmed.

Conservative, you're too tidy on the other side. "The cost of waiting is bounded: a small piece bought higher" assumes the piece is small and the gap is modest. If the print is clean and the stock gaps 20%, the miss isn't trivial, and a run to $427 is also possible. Missed upside is a real cost. It just isn't a capital loss, and I'd rather be honest that it exists. Your ex-payables test also needs care. The payables jump on the balance sheet was $570M, and if part of it is capex accruals, it never touched operating cash flow, since it flatters free cash flow instead. Strip the whole $570M from a $69.5M quarter and every print fails. Use the change-in-payables line from the cash flow statement and judge the trend, with inventory days falling and capex guidance flattening alongside it.

I also think "no adds before the print" is a rule that mostly matters in cases the cap already handles. If you're at the cap, you can't add. If you're below it, because you were underweight or already sold down, there's unused budget, and a small resting bid in the $262-275 area is a defensible use of it. I'd make it optional and low conviction. Your point that $270 sits under the 200-day, the 50-day and the middle band is fair. A fill there means the range probably already failed, so nobody should count on a bounce. Cancel it by the end of October, or earlier once a date is confirmed.

On the ladder, Conservative is right that a weekly close is checked once a week and ATR is 21 points a day, so the stock can be well through $255 before the rule fires. That's why the ladder is a backstop and the cap is the real control. Nobody should size above the cap because a ladder exists.

Here's the version I'd stand behind. Hold no more than the lower of half of standard or tolerable loss divided by 0.48, counting correlated optics names together until someone measures otherwise. If you're above that, sell the excess in two pieces: a real one at the open against the tape, and the rest on limit orders in the $321-332 zone that expire by the end of October. If you're at or below it, don't sell more and don't add at $319. A weekly close below $255.29 halves what's left, and a weekly close below $228.66 exits. After the print, put in a first piece the next session if capex guidance, inventory days and the cash flow statement's operating cash flow all improve, even if it gaps. Add the rest once the post-print level holds for a week.

The cost is the same as before. If COHR runs to $427, we own about half of what we could have. If it repeats the 48% drawdown, we lose about half as much. The disagreements left are about the optional tranche, and none of them changes the direction.

FINAL TRANSACTION PROPOSAL: SELL Neutral Analyst: Most of this has converged, so I'll take what's left in two parts: where each of you is still carrying something you haven't priced, and the version I'd stand behind.

Conservative, the market sale at the deadline is a good fix. A cap that depends on limit orders filling at a price the stock hasn't yet traded isn't a cap. I'd add that the cost is real: you may be selling the excess near 295 instead of 325, roughly 9% worse on that slice. That's the price of the cap and I'd pay it. I'd also tie the deadline to the earlier of the end of October or a few sessions before a confirmed date, and I wouldn't let the date sit unconfirmed. Treat the missing date as a reason to move the deadline earlier, not later.

Where I think you're still too tidy is "no adds before the print." You've persuaded me on the optional bid. Both of you agreed a fill near 270 probably means the range has failed, and "cheaper than $319" isn't an edge when valuation data is withheld. An exception that exists for people below the cap tends to get used on the worst day. So I'm dropping it, and that's a real change to the trader's plan: the pre-November tranche goes away and the rebuild moves to after the print. But the rebuild shouldn't be capped at half forever. Half of standard is a ceiling because we're carrying an undated print, an unexplained spike, and a cash-flow question. If the print resolves those, the case for the lower cap weakens, and the loss budget alone should decide how far to go toward full size. Keeping half as a permanent ceiling would trade one error for another.

Aggressive, you're right that missed upside is a cost, and I like that you dropped the $280-295 ceiling on the rebuild. But "the print is the price of admission" has a hole. A good print doesn't mean a good price. If the stock gaps 20% on clean numbers, the first piece buys resolved uncertainty at a price that already reflects it. That's fine, but it's not free, and the trader's plan shouldn't promise it will be cheap. Also, your concessions show how little the technical argument carries. ADX at 7 means the range edges are noisy, $270 isn't support, and the weekly stop is a backstop. What's left is the cash-flow story and event risk, and those argue for a cap and a post-print rebuild, not for any particular entry price.

One thing I want both of you to keep in view. This is a sizing call, not a verdict on the business. Revenue is up 34%, operating margin went from 9.5% to 14.9%, and net debt is about 1.3x EBITDA. Nobody here is saying the company is broken. The Sell is about the gap between a strong income statement and roughly negative $1.0B of trailing free cash flow, inventory at 187 days, and a price that jumped 10.9% on no verified news. It's also based on data that stops at the October 1 close, and today is the 2^nd. Anyone acting on it should look at the open first. If the jump turns out to have a real, verifiable catalyst, the "unexplained spike" leg of the case weakens and the cap should be reconsidered. If it gives back half, the first sale gets worse, and that's another reason not to anchor on $319.

Here's the version I'd hand over. Since I don't know the caller's book, size it by the lower of half of standard or tolerable loss divided by 0.48, counting the other optics names together until someone measures the correlation. If you're above that, sell the excess in two pieces: a real one against the tape at the open, and the rest on limits in the $321-332 zone with a market sale of anything unfilled at the deadline. If you're at or below it, don't sell more and don't add. If you're flat, don't buy at $319. A weekly close below $255.29 halves what's left, and a weekly close below $228.66 exits, but those levels are a backstop and the cap does the real work. After the print, if capex guidance, inventory days, and the change-in-payables line on the cash flow statement all move the right way, put in a first piece the next session, spread through the day, and the rest once the post-print level holds for a week. Then let the loss budget, not the half-size rule, set how far toward full size you go.

If COHR runs to $427, you'll own less than you could have. If it repeats a 48% drawdown, you'll lose about half as much. That's a trade I'd accept.

FINAL TRANSACTION PROPOSAL: SELL Neutral Analyst: I'll start with where I'm moving, because Conservative earned most of it.

The mid-October deadline is right. A cap that sits on unfilled limits for four weeks isn't a cap, and the slide back into the 294-298 cluster is exactly when the limits would sit idle. The close-below-298 trigger is also fine, though I want to say why, since I killed the $288 rule for whipsawing. That rule cut a position already at its cap. This one only finishes getting an oversized position down to the cap, so a whipsaw costs a slightly worse price on the excess, not a position we then have to rebuy. One refinement: it should be a close, not an intraday break. A close at 298 is only about 7% below here, roughly one ATR, so an intraday poke tells us nothing.

I'd also put numbers on "a real piece against the open," because nobody has. I'd say at least half of the excess. If the open gaps above 327, sell more into it. If it gaps below the 294-298 cluster, the rest goes that day.

Now the rebuild, where I think Conservative overcorrects. The test "cash and investments no longer falling, and no new financing" can't be met together. The June quarter burned $493M of free cash against a $1.99B cushion. For cash to stop falling without a raise, operating cash flow has to jump by hundreds of millions or capex has to fall by about the same amount, in one quarter. That isn't a test a good print passes. It's a test only a different company passes, and paired with a half-size ceiling until a second quarter, it means the rebuild effectively never happens. The cash test should be direction and runway: free cash burn narrowing from the minus $493M, operating cash flow measured on the cash flow statement's own payables line, and a stated funding runway.

On financing, my own rough math is that a $2B raise at a roughly $60B market cap is about 3% dilution. That's worth watching but small next to a 20-25% earnings gap either way. A raise should delay the first piece a few sessions while the stock digests it. It shouldn't veto the rebuild. And since a company can't promise it won't raise, "the call says nothing about financing" is weak evidence.

On two of three versus all, I don't think a count is the right frame, because the tests don't carry equal weight. Cash flow is the weak link all three of us agreed on. So make cash-flow direction a gate: if it fails, nothing goes in. If it passes, capex guidance and inventory days set the size of the first piece. That answers Conservative's drift worry without making a modest improvement in inventory days a veto.

On half of standard until a second quarter, I mostly agree. The loss cap binds below full size for most books, and I'll concede that "toward full size" will rarely be reachable. I'd allow one step: after one quarter that clears the gate on the stripped-down checks, which means the cash flow payables line and the unpaid-capex disclosure, the ceiling can move to about two-thirds. The full loss cap would wait for a second quarter. A quarter that passes those checks isn't flattered by payables timing, which was the reason for waiting two.

Aggressive, one thing on your "only company-sourced information reopens the cap." I agree a broker note doesn't touch the burn. But it should cut both ways. A guidance cut, a shelf filing or a customer problem should shrink the cap just as a better capex outlook could loosen it. A confirmed report date should also move the deadline even though it says nothing about cash flow. And Conservative, a gap at the open isn't a catalyst, but I'd still look at it before executing, since our data stops at the October 1 close and this is the 2^nd.

I'll end with how complicated this has gotten. Every extra rule is one more a holder can misapply, so here is the short version. Hold no more than the lower of half of standard or tolerable loss divided by 0.48, counting the other optics names together. If you're above it, sell about half the excess against the open and the rest on limits at 321-332 that expire by mid-October, or earlier if a date is confirmed, then sell what's left at market. A close below 298 before then sells the rest of the excess. Don't add before the print, and don't buy at $319 if you're flat. A weekly close below $255.29 halves what's left, and one below $228.66 exits, but those are backstops and the cap does the real work. After the print, nothing goes in unless cash-flow direction passes, and then the first piece is small and spread through the day. The ceiling moves to about two-thirds after one clean quarter and to the loss cap after two.

If COHR runs to $427, we'll own less than we could have. If it repeats the 48% drawdown, we'll lose about half as much. That's an acceptable trade for a business this good with a cash flow this unproven.

FINAL TRANSACTION PROPOSAL: SELL

V. Portfolio Manager Decision¶

Portfolio Manager¶

Rating: Underweight

Executive Summary: Cut COHR to a capped position. Hold no more than the smaller of about half a standard allocation or (tolerable loss ÷ 0.48), and count other optics names (LITE, AAOI, CIEN, VIAV) against the same budget until you have measured how closely they move together. If you are above the cap, sell about half of the excess at the Oct 2 open based on what the market is actually showing, not on the $319 close. Put the rest on limit orders at $321-332 that expire by mid-October, or a few sessions before a confirmed earnings date. Sell anything still unfilled at market, and also sell the rest of the excess on any daily close below about $298. Add nothing before the November print, and if you have no position, don't open one at $319. A weekly close below $255.29 halves what's left and one below $228.66 closes it out. Rebuild after the print only if cash flow is clearly moving the right way. Horizon is 1-3 months.

Investment Thesis: Decision: Underweight, not Sell. All three risk analysts ended up labelling their view SELL, but every version of their plan reduces the position to a cap rather than closing it. On this scale that is Underweight ("reduce exposure, take partial profits"). Sell here means exit or avoid, and that would throw away a real improvement in the business. The research manager also chose Underweight.

The business is improving. Revenue was $2.05B, up 33.7% year over year. Sequential growth sped up four quarters in a row (+3.4%, +6.6%, +7.1%, +13.3%). Operating margin rose from 9.5% to 14.9%, normalized EBITDA margin from 17.4% to 25%, and the incremental operating margin was about 32%. Net debt is about 1.3x EBITDA, so solvency is not the issue, and the preferred stock has converted. That is why nobody argued for a short or for selling everything.

Three things drove the cut: 1) Cash conversion. Over the last four quarters, operating cash flow was about $80M against about $805M of net income. Free cash flow was about -$1.03B. June capex was $563M, four times a year earlier. Inventory is $2.58B, up 80%, or about 187 days versus 133. Cash and investments fell $430M in one quarter to $1.99B. June operating cash flow was helped by payables jumping $570M, and any capex accruals in that jump mean the cash capex figure understates the real build rate. 2) Price versus value. The research manager calculated about $316 from the bull's own scenario weights, or $307-312 when the miss case is moved to the bull's own $180-185 tripwire. That is below $319 and well short of the 6-7% hurdle. The stock trades at about 37x June-annualized EBITDA and about 30x the bull's FY27 EBITDA. The Neutral analyst fairly pointed out that this sits within the error of an exercise done without vendor valuation data, so it only argues against adding, not for exiting. 3) Technicals and event risk. ADX is 7, so the stock is in a range. The daily SuperTrend points down with its stop at 332.01. Price closed under resistance at 321.52, 327.15 and 332.01. The Sep 21 high of $321.52 turned into $290.61 three sessions later. The 10.9% jump on Oct 1 has no verified catalyst and looks like an optics-sector move. With a daily ATR of 6.7%, a November gap can go straight through any stop. Insider activity is selling only, but it is small and steady, so I treat it as neutral to mildly negative.

What I took from the debate: - I adopted the Conservative analyst's loss-budget sizing: max position = tolerable loss ÷ 0.48, based on the 48% fall from $426.89 to $222.05 in June-July. Use the smaller of that and half a standard allocation. The research manager's 25-35% of standard is the right end for books already heavy in optics. - The Conservative analyst's headroom argument holds, which is why the research manager's pre-November $265-275 tranche is dropped. A fill there would mean the stock had already broken below the 200-day, the 50-day and the middle Bollinger band, and it would use up a loss budget that is already committed. - Unfilled limit orders get sold at market by the deadline, so the cap does not depend on fills. - The daily $288 stop was dropped because it would have sold on Sep 30, the day before the 10.9% rally. Weekly closes below 255.29 and 228.66 are backstops only. - After the print, the cash-flow trend is a gate. If free cash burn is not narrowing from -$493M, judged on the cash flow statement's change-in-payables line and the unpaid-capex disclosure, nothing goes in. If it passes, capex guidance and inventory days set the size. Buy the first piece the next session, spread through the day, even if the stock gaps above the old $280-295 band. Add the rest once that level holds for a week. The ceiling rises to about two-thirds of standard after one clean quarter and to the full loss cap after two. - An equity raise or shelf filing delays the rebuild. It does not cancel it.

What would change the call: - Upgrade to Overweight if FY27 capex guidance is about $2.1B or less, operating cash flow tops 50% of EBITDA, gross margin stays at 38% or higher, and inventory days head toward the 160s. Only company-sourced information counts here; a new broker note does not. - Close out the remaining position if gross margin falls below 38%, inventory days exceed 200, sequential growth drops below 3% while inventory days rise, payables unwind while operating cash flow stays near zero, or there is a guidance cut or a large equity raise.

Price target: $310. Two separate methods land in the same place: (a) the research manager's scenario value with the miss case updated, $307-312, midpoint about $310; (b) the technical base case, a range of roughly $294-327 while ADX stays under 20, midpoint about $310.5. That implies about 3% downside over the period, too little to hold full size against ATR-level volatility and an undated print.

Data gaps: - No vendor valuation, peer multiples, guidance, backlog or consensus. - The November earnings date is unconfirmed. - The sell-side notes came secondhand from StockTwits. - The roughly $2B equity raise and the $44M write-off still need checking in the filings. - Data stops at the Oct 1 close.

Current Price: 319.19

Price Target: 310.0

Confidence: Medium

Time Horizon: 1-3 months